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Abstract 
 
The human DMD locus encodes dystrophin protein. Absence or reduced levels of dystrophin (DMD 
or BMD phenotype, respectively) lead to progressive muscle wasting. Little is known about the 
complex coordination of dystrophin expression and its transcriptional regulation is a field of intense 
interest. In this work we found that DMD locus harbours multiple long non coding RNAs which 
orchestrate and control transcription of muscle dystrophin mRNA isoforms. These lncRNAs are 
tissue-specific and highly expressed during myogenesis, suggesting a possible role in tissue-specific 
expression of DMD gene isoforms. Their forced ectopic expression in human muscle and neuronal 
cells leads to a specific and negative regulation of endogenous dystrophin full lenght isoforms. An 
intriguing aspect regarding the transcription of the DMD locus is the gene size (2.4Mb). The 
mechanism that ensures the complete synthesis of the primary transcript  and the coordinated 
splicing of  79 exons is still completely unknown. By ChIP-on-chip analyses, we discovered novel 
regions never been involved before in the transcription regulation  of the DMD locus. Specifically, 
we observed enrichments for Pol II, P-Ser2, P-Ser5, Ac-H3 and 2Me-H3K4 in an intronic region of 
3Kb (approximately 21Kb) downstream of the end of DMD exon 52 and in a region of 4Kb 
spanning the DMD exon 62. Interestingly, this latter region and the TSS of Dp71 are strongly 
marked by 3Me-H3K36, an histone modification associated with the regulation of splicing process. 
Furthermore, we also observed strong presence of open chromatin marks (Ac-H3 and 2Me-H3K4) 
around intron 34 and the exon 45 without presence of  RNA pol II. We speculate that these two 
regions may exert an enhancer-like function on Dp427m promoter, although further investigations 
are necessary. Finally, we investigated the nuclear-cytoplasmic compartmentalization of the 
muscular dystrophin mRNA and, specifically, we verified whether the exon skipping therapy could 
influence its cellular distribution. 
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Introduction 
 
Duchenne and Becker Muscular Dystrophies: an Overview 
 
There are more than 30 different types of inherited dystrophies that are characterized by muscle 
wasting and weakness of variable distribution and severity, manifesting at any age from birth to 
middle years, resulting in mild to severe disability and even short life expectancy in the worse 
cases. Clinical and pathological features are generally the parameters to classify the most common 
type of Muscular Dystrophies (MDs). The broad spectrum of MDs arises from many different 
genetic mutations that reflect defects not only in structural proteins, but also in signaling molecules 
and enzymes. Dystrophin was the first mutant structural protein shown to cause MD. The DMD 
gene codes for dystrophin and mutations in the DMD gene range from single-nucleotide changes to 
chromosomal abnormalities (http://www.dmd.nl/). The two more common type of dystrophy, both 
defined as X-linked muscle disorder, are the severe Duchenne muscular dystrophy (DMD OMIM 
300677) due to out-of-frame mutations, and the milder Becker muscular dystrophy (BMD OMIM 
300376) caused by in-frame mutations. Some “exceptions to the reading frame rule” are associated 
with intermediate phenotypes. These involve both patients with BMD who carry frame-shift 
deletions/duplications or DMD with in-frame deletions/duplications. Moreover  an increasing 
number of mutation in the DMD gene have been shown to result in severe dilated cardiomyopathy 
with no apparent skeletal muscle pathology. The term X-linked dilated cardiomyopathy (XLDC 
OMIM #302045) has been assigned to this clinical phenotype (Davies and Nowak, 2006; Ferlini et 
al., 2013).  The incidence of DMD is estimated at 1 in 3500 male newborns with a prevalence of 6 
in 100,000 males (Emery, 1991). DMD is characterized by weakness of leg, pelvic and shoulder 
girdle muscles starting in early childhood. By the early teens, the heart and respiratory muscles also 
are affected. The average life expectancy for patients afflicted with DMD is around 25. BMD is a 
milder variant than DMD with a better prognosis. Incidence of BMD is approximately 1 in 18.450 
males and prevalence is 2.4 per 100,000 in the general population (Bushby et al., 1991) and the 
course is slower and less predictable than that of DMD. Its onset is between the age of 3 and 21 
years with a mean age of onset at 11 years. Age at death is 21–89 years with an average age of 
about 45 years (Bushby and Gardner-Medwin, 1993; Hermans et al., 2010). 
The majority of female carriers of DMD mutations are asymptomatic, nevertheless, a certain 
number, defined as “manifesting” or “symptomatic”, develop symptoms of the disease, which vary 
from a mild muscle weakness to a DMD-like clinical course. Despite intensively explored, the 
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pathogenic mechanism underlying clinical manifestation in DMD female carriers still remains a 
controversial issue (Brioschi et al., 2012). 
The dystrophin is a large protein that acts as elastic bridge between the cell cytoskeleton and the 
extracellular matrix to stabilize the sarcolemma. Dystrophin belongs to the protein system involved 
in force transduction in muscle membrane. It is part of a multimeric protein complex called 
dystrophin–glycoprotein complex (DGC). Via syntrophin, a member of DGC, the enzyme neuronal 
Nitric Oxide Syntase (nNOS) is also localized to the membrane of muscle fibers and it regulates a 
sub-set of muscular gene-targets by modulation of histone deacetylases (HDACs) activity. Absence 
of the dystrophin protein (DMD) and reduced levels or abnormal configuration of dystrophin 
(BMD) leads to membrane fragility making muscle cells susceptible to damage from contraction 
(Petrof et al., 1993). Secondary, increase in free radicals and the impairment of nNOS-signalling are 
thought to further contribute to muscle degeneration. Moreover, as muscle disease advances, muscle 
repair and regeneration cannot adequately compensate for damage, leading to degeneration and 
necrosis of skeletal myofibers and cardiomyocites and gradual replacement by fibrofatty tissue 
(Durbeej and Campbell, 2002; Ervasti and Sonnemann, 2008; Wallace and McNally, 2009). 
For this and other reasons, from over a decade, several attempts have been made in order to find a 
cure for DMD, but the dystrophin gene complexity, its fine regulation, the structural function of the 
protein as well as the large body muscle mass to be treated, including the heart, have raised many 
difficulties in offering an efficacious and safe treatment. 
 
Exon Skipping: a Promising Therapeutic Approach for DMD 
 
In the DMD patients, large deletions of one or more exons are the most common mutational event  
(accounting for the 65% of the dystrophin mutations) that lead to a disrupted reading frame (see 
Leiden Muscular Dystrophy Pages website), thus precluding the production of the muscular 
dystrophin protein and leading to progressive muscle weakness, cardiomyopathy and respiratory 
failure. Deletions are typically clustered in a hot-spot region between exons 45 and 55, and less 
commonly in a second deletion hot-spot towards the 5′ end of the gene (between exons 3 and 7). At 
present there is no effective therapy to stop the lethal progression of the disease, although several 
promising experimental strategies are currently under investigation (Ferlini et al., 2013). 
The observation that the milder allelic variant BMD caused by in-frame mutations allows the 
translation of a smaller but partially functional dystrophin provided the strong rationale for the 
application of the exon skipping strategy to DMD. The final goal of this therapeutic strategy is 
overcoming an out-frame mutation in the muscular dystrophin transcript to convert the severe DMD 
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phenotype into the milder BMD form. Patients with BMD are able to retain ambulation into late 
adulthood and have a normal lifespan.  
Although many different antisense oligonucleotide (AON) chemistries exist, so far, two classes are 
under clinical experimentation: 2′O-methylphosphorothioate oligoribonucleotides (2′OMe) and 
phosphorodiamidate morpholino oligomers (PMOs). Both chemistries, by direct sequence-specific 
steric block via hybridization to pre-mRNA,  target specific exons  to alter pre-mRNA splicing and 
causing their skipping during the splicing process. Given that most of the critical functional 
domains within the dystrophin protein are at the amino and carboxyl terminals and in the cysteine-
rich domain, the resulting shortened dystrophin protein product retain still its structural activity, 
because partly deleted of internal sequences that encode spectrin-like rod repeat domains 
(Fairclough et al., 2013).  
AONs have been extensively and successfully tested in vitro (Dunckley et al., 1998) and, more 
importantly, in vivo (Aoki et al., 2012; Goyenvalle et al., 2010; Yokota et al., 2012). Proof of 
principle has been established in Phase I and Phase II clinical trials led by groups in the Netherlands 
(Leiden University Medical Centre in collaboration with Prosensa–GlaxoSmithKline) and the 
United Kingdom (MDEX Consortium in collaboration with Sarepta Therapeutics), targeting DMD 
exon 51, an approach that is applicable to ~13% of patients. The 2′-O-methyl-phosphorothioate 
(2′OMe) and morpholino phosphorodiamidate oligonucleotide (PMO) AONs used in these trials 
were well-tolerated and restored dystrophin protein to variable degrees (Cirak et al., 2011; Goemans 
et al., 2011; Kinali et al., 2009; Mercuri and Muntoni, 2013; van Deutekom et al., 2007). 
Despite the encouraging results, several hurdles limiting the therapeutic approach have to be 
overcome, such as the poor cellular uptake of AONs, either when delivered via intramuscular or  
systemic routes, and their relative rapid clearance from circulation, which means repeated 
administrations and probably a lifelong treatment. Another important matter to consider is  the high 
variability in exon-skipping efficiency among different muscle types. Furthermore, the use of AON-
mediated exon skipping therapy is still limited by the fact that they cannot be utilized for a 
significant number of DMD patients, in particular those with large deletions or with mutations in 
regulatory or N-/C-terminal regions of dystrophin (Aartsma-Rus et al., 2009; Benedetti et al., 2013).  
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Figure 1. A) Human DMD Locus; B) Dystrophin isoforms; C) dystrophin-glycoprotein complex; D) Out-of -frame and In-frame DMD mutation 
(Fairclough et al., 2013; Muntoni et al., 2003) 
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The Human DMD Locus 
  
The Overall Organization of the Human DMD locus 
 
The gene encoding dystrophin (DMD) is the largest gene in the human genome and accounts for 
approximately 0.1% of the entire human DNA sequence; it is 2.4 Mb long and it lies on the short 
arm of the X chromosome  (Xp21.2). It consists of 79 exons, 78 introns and at least 7 recognized 
promoters that give rise to 7 different dystrophin isoforms, each displaying a tissue- and temporal-
specific pattern of expression. Three main promoters, the ancient Brain (B), the Muscular (M) and 
the Purkinje (P) promoter, drive the expression of the three full length isoforms, each contain 
unique first exon, spliced with a common set of 78 exons. The 14kb messenger RNA encode a 
protein with a molecular weight of 427 kDa. The skeletal and cardiac muscles are the main tissues 
where the Dp427m isoform is expressed, whereas the Dp427b (also named Dp247c) isoform is 
predominantly expressed in the brain (hypothalamus and cortex) and also, at low levels, in striated 
muscles. The Dp427p isoform is expressed in Purkinje cerebellar neurons, and, at very low 
concentrations, in skeletal muscle.  Four internal promoters, named retinal (R), brain-3 (B3), 
Schwann cell (S), e general (G), give rise to shorter dystrophin proteins. Each of these promoter use 
a unique first exon (exons 29, 44, 55 and 62) that splices into exons 30, 45, 56, and 63 to generate 
protein products of 260 kDa (Dp260), 140 kDa (Dp140), 116 kDa (Dp116), and 71 kDa (Dp71), 
respectively. Dp260 is expressed in high concentrations in the retina, where it coexists with the full-
length brain and muscle isoforms (D'Souza et al., 1995; Pillers et al., 1993). Dp140 is expressed in 
brain, retina, and kidney tissues (Lidov et al., 1995). Dp116 is only expressed in adult peripheral 
nerves (Byers et al., 1993). Dp71 is detected in most non-muscle tissues including brain, retina, 
kidney, liver, and lung and is present in cardiac but not in fully differentiated skeletal muscle. It is 
denoted as ubiquitous dystrophin isoform (Bar et al., 1990; Rapaport et al., 1992; Sadoulet-Puccio 
and Kunkel, 1996).  
In addition to these isoforms, the dystrophin gene produces many isoforms generated through 
alternative splicing events. These splice variants are formed both through the exclusion of some 
exons from the primary transcript (exon skipping) and by subversion of the reciprocal order of 
exons (exon scrambling) (Sadoulet-Puccio and Kunkel, 1996; Surono et al., 1999). These events, 
which commonly occur in a tissue-specific way, generate further protein diversity and account for 
the complex expression regulation of  the tissue-specific dystrophin functions (Muntoni et al., 
2003). 
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The Introns of DMD Locus 
 
The full sequencing of dystrophin introns has revealed that very large and in some cases huge 
introns are very common in the architecture of this gene, in particular the introns close to alternative 
transcription starting sites (as introns 1-Muscle, intron 1-Brain and intron 1-Purkinje, as well as 
intron 44) . Indeed, the intronic sequences account for more than 99% of the DMD locus length and 
this intriguingly aspect suggest that such genomic portion conserves sequences or structural features 
performing essential function or containing important regulatory domains. The DMD Leiden pages 
(http://www.dmd.nl/) report all the known intronic sequences and their relative accession numbers 
in the HGMP GeneBank. Furthermore, the detailed analysis of the large introns, emerging from the 
full Genome Project sequencing, have revealed interesting characteristics and focused attention on 
possible roles and functions they may play in gene regulation, especially transcription and splicing 
(McNaughton et al., 1998; McNaughton et al., 1997). 
Another controversial matter regarding the DMD locus is the high occurrence of alternative splicing 
events occurring in this gene that raised the question why such large introns have been maintained 
during evolution. Their unusually large size has been asserted as one of the major causes of the high 
mutation rate known to occur in some regions of the gene, which give rise to two well known 
mutation hot-spot regions (exons 3-7 and exons 44-53). The genomic breakpoint  of such hot-spots 
frequently lies within introns 2 and 7 or interest predominantly  the  intron 44 (Muntoni et al., 2003; 
Nobile et al., 1995). In particular, although the introns 7 and 44 experience the highest 
recombination rates of the dystrophin gene, they seem to be sites of positive directional selection 
(Nachman and Crowell, 2000). This support the idea that possible regulatory motifs  are contained 
within. Intron 7 is adjacent to a region of “exceptions to the rule” of the Monaco open-reading-
frame theory (Monaco et al., 1988); in fact a restarting dystrophin ATG located within exon 6 has 
been postulated as mechanism to rescue dystrophin translation in mutations located within exon 2–6 
(Gurvich et al., 2009). These mutations cause a BMD phenotype despite of being out-of-frame, 
pointing out again that this region might be involved in regulatory processes.  
To date, the co-transcriptional splicing mechanism of human huge introns is yet a controversial 
question. In a recent study, it has been proposed a ‘nested splicing hypothesis’ where many splice 
site-like sequences within the large intron could play roles in splicing events of nested introns, 
bringing the distant authentic splice sites into close proximity to facilitate the final splicing (Suzuki 
et al., 2013). 
Notably, introns are the segments involved in the DNA duplication process and duplication forks 
formation, fact that is mechanistically linked to the gene disruption due to non-allelic homologous 
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recombination (NAHR), non-homologous end joining (NHEJ), and microhomology-mediated 
replication-dependent recombination (MMRDR) mechanisms, known to explain DNA 
rearrangements associated with genomic disorders (Ferlini et al., 2013). In the human dystrophin 
gene an unusual extended area of DNA association with nuclear matrix was been characterized and 
defined as an extended DNA loop anchorage region (LAR) spanning approximately 200 Kbp and 
covering a part of the intron 43, exon 44, and most of large intron 44. The extended LAR identified 
harbors the major recombination hot-spot of the dystrophin gene and also a replication origin. 
Because of the mechanisms determining positions of deletion hot-spots in DMD locus is not yet 
understood the author of this paper proposed a model where DNA topoisomerase II-mediated 
cleavage at the nuclear matrix may enhance recombination events within this extended LAR 
(Iarovaia et al., 2006). 
Taken together, all these points of view enhance the idea that behind the large DMD introns are 
hidden several more information of that we think. 
 
Transcriptional Dynamics of the DMD Locus 
 
The Transcription Rate of DMD Locus  
 
Monitoring the transcript accumulation from four different sites within the gene, it is estimated that 
RNA polymerase II (Pol II) takes 16 hours to transcribe the entire DMD locus at an average 
elongation rate of 2.4 Kb min-1.The rate of transcript accumulation seems to be reduced at the 3’ 
end of the gene relative to the 5’ end. This could be due, at least in part, either to the exceptional 
length of the dystrophin gene or the nature of internal DNA promoter sequences difficult to 
transcribe, likely because bound by transcriptional repressors that might interfere with the 
extraordinary journey of RNA polymerase II along the entire locus.  
The mechanism that ensures  a coordinated splicing of  79 exons is another important matter 
regarding the full length dystrophin transcript . Although this aspect is still unclear, lines of 
evidence showed that both splice site selection and splicing occur in a orderly manner, in a 5’ to 3’ 
direction, on the nascent dystrophin transcript and before transcription is complete (co-
transcriptional splicing)(Tennyson et al., 1995). Measurements by quantitative RT–PCR indicated 
that mature dystrophin mRNA is 5–10 per nucleus in adult skeletal muscle tissue. This result is 
consistent with other studies indicating the dystrophin is a low abundance transcript and is 
comparable with the level of transcript expressed in myogenic cultures (Tennyson et al., 1996). 
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The precursor mRNA and mature mRNA are the main target of the most promising molecular 
therapies aimed to rescue a muscular full-length protein production in DMD patients. In the first 
case, as said above,  the exon skipping approach aims to reframe the DMD transcripts redirecting 
pre-mRNA splicing of dystrophin. In the second one, the read-through  of stop codons strategy uses 
compounds that force the cell to ignore premature stop codons during translation process. Both the 
approaches rely on the quantification of muscle dystrophin expression level and, overall, on the 
stability of the transcript to monitor the therapeutic potential success.  
Since DMD transcripts can generally picked up in patient-derived muscles, many efforts have been 
made to correlate the type of mutation  to amount of muscle dystrophin and the related phenotype. 
Mostly by microarray-analysis, several reports have attempted to quantify the DMD transcripts, 
concluding that the DMD gene is less expressed in DMD patients compared with controls (Chelly et 
al., 1990). Recently, a very appealing technology, a Custom Micro-Fluidic Exome Array (named 
FluiDMD), allow to profile which dystrophin isoforms are expressed in a dystrophic sample and 
establish changes in mRNA decay,  among several  pathogenic effects caused by mutations in the 
dystrophin gene. Both features are linked to the transcriptional dynamics of the DMD locus 
(Bovolenta et al., 2012b). However, latest lines of evidence focused the attention on the 5'-3' 
imbalance of the muscle dystrophin transcript rather than the transcriptional rate, suggesting that 
this is an important phenomenon that determines the dystrophin protein levels. The authors of this 
paper demonstrated that mutated transcript in the mdx mouse model shows a stronger 5' to 3' 
imbalance compared with that of its wild-type counterpart and reading frame restoration via 
antisense-mediated exon skipping does not correct this event.  They also report significant transcript 
instability in human BMD samples, supporting the theory that  transcript imbalance is not caused by 
premature nonsense mutations (Spitali et al., 2013).  
Nonetheless, the export of Dp427m transcript into the cytoplasm is another important process that 
determine the final amount of dystrophin protein in muscle cells. The mRNA can be either 
committed for export to the cytoplasm or accumulates  in the nucleus where it may be degraded. 
Formation of an export-competent messenger ribonucleoproteins (mRNP) begins at transcription. 
Progressively, mRNAs are channeled into the specific export pathway coordinately with their 
processing and assembly into mRNPs. Among the factors bound to the pre-mRNAs are also export 
adaptors that serve to establish a physical bridge between the mRNA molecule and  its export 
receptors (Carmody and Wente, 2009; Köhler and Hurt, 2007). Importantly, several studies 
demonstrated that the factors involved in mRNA processing specify the fate of a transcript. Thus, if 
a transcript is not properly processed, it can be recognized by the nuclear surveillance machinery, 
retained in the nucleus and degraded by the nuclear exosome. This has been documented in elegant 
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studies of mutants that are defective in mRNA splicing, export and polyadenylation (Brodsky and 
Silver, 2000; Carmody and Wente, 2009; Hilleren et al., 2001; Lei and Silver, 2002; Libri et al., 
2002; Zenklusen et al., 2002) For these reasons the export process should be taken into account in a 
dystrophic context. The availability of dystrophin mature transcripts is a key factor to determine the 
protein abundance and thus will influence the outcome of mRNA-targeting therapies.  
 
The Transcriptional Regulation of Muscle Dystrophin Isoform 
 
In terms of tissue-specific expression, the muscular dystrophin isoform is transcribed mainly in 
skeletal and cardiac muscle tissue and to a lesser extent in smooth muscle, kidney and brain. It 
accumulates as normal myoblasts differentiate in multinucleated myotubes (Chelly et al., 1988). 
Regulation of DMD gene expression in muscle is complex and appear to require several cis-
regulatory elements and trans-acting factors that drive its transcription in a tissue- and temporal- 
specific pattern. 
In early molecular and functional studies about muscle-specific promoter region, some of these cis-
acting sequences and trans-acting factors have been defined as involved in myogenic regulation of 
DMD gene transcription. The upstream  region of muscle dystrophin exon 1 was compared to that 
of other muscle-specific gene promoters. Sequences analysis indicated that in addition to an ATA-
rich region (at position -24), thought to bind RNA polymerase II, and the GC box (at position -61), 
this region contains most relevant conserved domains implicated in the regulation of other muscle-
specific genes: a CArG box at -91 bp; myocyte-specific enhancer-binding nuclear factor 1 (MEF-1) 
binding site homologies at -58, -535, and -583 bp and a muscle-CAAT (MCAT) consensus 
sequence at -394 bp relative to the cap site. The 850 bp of 5’-flanking the transcriptional start site of 
muscle dystrophin isoform is capable to drive the DMD gene transcription in a cell- and 
developmental stage-specific manner. More specifically, the 149 bp-promoter fragment  upstream 
of muscle exon 1  contains the cis-acting sequences required for a preferential muscle-specific 
activation of DMD transcription (Klamut et al., 1990). Although also a well-conserved putative E-
box element has been found at -49 position  in the minimal promoter fragment, this motif is not 
involved in the dystrophin muscle-specific transcription, because it was non-responsive to trans-
activation by the known binding myogenic master regulator, MyoD (Myogenic Dyfferentiation 1 
factor) (Gilgenkrantz et al., 1992; Weintraub, 1993).  
In independent studies the CArG box motif was shown to be an essential functional regulatory 
element. This element revealed to have different trans-acting factor binding properties depending on 
the combined activity of several regulatory protein, which determine different transcriptional 
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outcome. Immediately downstream  of CArG box motif, the partially overlapping sequence 
GAAACC seems necessary for a tissue-specific promoter activity. The first one is recognized by 
the positive serum response factor (SRF), which in turn requires the activity of the dystrophin 
promoter bending factor (DPBF) bound to second one. Since SRF alone is not sufficient to drive 
muscle-specific transcription, it has been postulated that the nuclear factor DPBF functions as an 
architectural component which induces a conformational change in the dystrophin promoter, likely 
allowing SRF to interact with other muscle-component of the transcriptional complex (Galvagni et 
al., 1997). Dystrophin CArG box element is also recognized by another bending factor, YY1, a zinc 
finger protein that, in a muscular cellular context, acts as a negative regulator of the dystrophin 
promoter.  DPBF and YY1 compete each other to regulate the promoter activity  and exert an 
opposite effect of bending on double helix. These results suggest that an alternative spatial 
organization of the dystrophin promoter could be relevant for its transcriptional regulation. 
Moreover, YY1 seems regulate the promoter activity in a developmental specific manner. Indeed, 
an up-regulation of promoter correlates with a down-regulation of  the factor YY1 during muscular 
cell differentiation (Galvagni et al., 1998). 
However, further transgenic mouse studies demonstrated that the muscle dystrophin promoter alone 
drives the lacZ reporter gene expression only in the right ventricle of heart. No promoter activity 
was reported in mature skeletal muscle, thus providing indirect evidence that additional muscle-
specific regulatory control elements are necessary to target the rest of heart as well as the entire 
skeletal muscle tissue (Kimura et al., 1997). 
Functional analysis of a 36 kb region surrounding  the muscle transcription start site has identified a 
muscle-specific enhancer within intron one of the dystrophin gene (DME1; dystrophin muscle 
enhancer one) positioned 6.5 kb downstream of muscle exon one (Klamut et al., 1990). This 5kb 
fragment exhibits properties consistent with a muscle-specific transcriptional enhancer since it was 
shown to be inactive in fibroblasts and functionally independent of position and orientation.  
Although this regulatory element was shown to have a positive influence on the transcriptional 
activity of the dystrophin muscle promoter in both immature and mature skeletal muscle, as well as 
in transgenic mice engineered to express lacZ reporter gene under control of mouse dystrophin 
muscle promoter/enhancer sequences, it seems to have higher activity in cardiac muscle-derived 
cells as compared to skeletal muscle-derived cells. To date the exact role of DME1 in the regulation 
of endogenous dystrophin gene transcription in skeletal and cardiac muscle remains unclear 
(Bastianutto et al., 2001; Klamut et al., 1996; Marshall et al., 2002). 
The intron 1 enhancer activity and the muscle dystrophin promoter are not sufficient to fully explain 
the transcriptional dynamics of the DMD locus in terms of developmental and spatial regulation and 
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point to the existence of both additional cis-acting enhancer elements in other regions of the DMD 
gene and several other trans-acting factors/molecules that drive its transcriptional regulation in the 
skeletal and cardiac muscle compartments. However, since the enhancers can be located up to 
hundreds of kilobases from the promoters that they control, their identification become challenging. 
In fact, they are able to establish long range interactions with the promoters of regulated genes and 
act independently of orientation of transcription. 
Without doubt, the general mechanism underlying the fine spatio-temporal transcriptional 
reglutation of muscle dystrophin needs many further efforts to be deeply understood. 
 
Non coding RNAs in Muscle Biology 
 
Muscle is a dynamic tissue that goes through many recurrent phases of degeneration and 
regeneration throughout an individual’s lifetime. During normal muscle development, specific 
molecular circuitries and signaling pathways control several events in different cell types such as 
activation of satellite cell proliferation, progenitor cell maintenance, myoblast differentiation, 
muscle cell homeostasis and immune cell recruitment. It is therefore not surprising that their 
deregulation heavily contributes to the degeneration of dystrophic muscles and they are the object 
of intense research (Marrone and Shcherbata, 2011).  
There is a continuous flow of scientific reports that underpin functional links between non-coding 
RNA molecules (ncRNAs) and skeletal muscle biology, suggesting that these ones can play a 
crucial function both in physiological muscle development and in pathological muscle disorders. 
Transcription of the eukaryotic genome yields only 1–2% of protein coding transcripts and the 
remainder is classified as non-coding RNAs (ncRNAs). In other words, non-coding RNAs are the 
main output of the global transcription process, highlighting the idea that such an intense cellular 
effort cannot be just simple noise. Rather, it is reasonable to speculate that this underscored 
transcriptome possesses specific vital functions (Carninci et al., 2005; Kapranov et al., 2007; 
Mattick and Makunin, 2006).  
In general, non-coding RNAs are divided into structural and regulatory RNAs. The first ones 
include ribosomal, transfer, small nuclear and small nucleolar RNAs (rRNAs, tRNAs, snRNAs and 
snoRNAs, respectively), which have been deeply characterized at the functional level. The second 
ones are a very broad class of RNAs whose main categorization essentially relies on their length.  
Small ncRNAs are defined as transcripts shorter than 200 nucleotides. The most functionally 
characterized are microRNAs (miRNAs), piwi-interacting RNAs (piRNAs) and small  
interfering RNAs (siRNAs), which are critical for the assembly and the activity of the RNA 
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interference machinery. RNAs longer than 200 nucleotides are named long non-coding RNAs 
(lncRNAs) and are a very heterogeneous group of molecules. Because there is not an official way to 
classify them, they can be placed in one or more categories depending on their genome localization 
and/or on their orientation (sense, antisense, bidirectional, intronic or intergeniclncRNAs) (Ponting 
et al., 2009; Wang et al., 2011).  
The emerging studies about this intriguing category of molecules are revealing that  ncRNAs are 
tightly interconnected with the main fundamental aspects of muscular tissue, both in physiological 
and in pathological contexts, revealing that they are important players in processes such as cellular 
lineage commitment, growth and differentiation of skeletal muscle. Since muscle differentiation and 
regeneration are key features that require to be considered when designing novel therapies, 
addressing the role of ncRNAs in MDs is of high clinical relevance. Furthermore, regulatory RNAs 
may serve as biomarkers, providing information on disease course, disease severity and response to 
therapies. Aberrant expression levels of non-coding RNAs can result in novel types of defects that 
cause remarkable changes in processes such as mRNA maturation, translation, signaling pathways 
or gene regulation. To date, it is clear that there is involvement of several miRNAs in the muscular 
dystrophies, on the contrary, very little is known about the role of long ncRNAs (Erriquez et al., 
2013). 
microRNAs control the stability and/or the translational efficiency of target messenger RNAs, thus 
causing post-transcriptional gene silencing. Mammalian miRNAs are transcribed as long primary 
transcripts (pri-miRNAs) and encode one or more miRNAs. Then, they are further processed to 
yield ~22 bp mature transcripts. miRNAs actively take part in the proliferation and differentiation 
of skeletal muscle cells as an integral component of genetic regulatory circuitries.  miR-1, miR-
133a/b and miR-206 are largely studied and defined "muscle-specific" miRNAs (myomiRs). They 
are regulated in muscular transcriptional networks via myogenic regulatory factors (MRFs) and via 
others key-regulators of the myogenic program, MEF2 (myocyte enhancer factor 2) and SRFs 
(serum response factors). Recently, a new regulatory pathway, the mechanistic target of rapamycin 
(mTOR) signaling was seen to regulate miR-1 expression and was also found responsible for MyoD 
stability (Liu et al., 2007; Rao et al., 2006; Rosenberg et al., 2006; Sun et al., 2010; Zhao et al., 
2005). It is possible to functionally define miR-133 as enhancer of myoblast proliferation while 
miR-1 and miR-206 as enhancers of skeletal muscle differentiation (Chen et al., 2009; Eisenberg et 
al., 2009; Ge and Chen, 2011; van Rooij et al., 2008). 
Interestingly, many miRNAs are defined as “non-muscle specific” (or also ubiquitously expressed), 
because essentially they are not exclusively expressed in muscular tissue. It has been demonstrated 
that they also play key-roles in modulating important pathways involved in the regulation of 
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muscular metabolism and cellular commitment. Some of these miRNAs counteract the 
differentiation process since their activity is aimed to positively regulate the proliferation phase 
during muscular development. In contrast to this set of miRNAs, many other “ubiquitous” miRNAs 
exert an active role in muscle differentiation through different mechanisms. An up-to date list of 
miRNAs involved in muscle biology are reported in two recent reviews providing for each miRNA 
the context in which they were studied and highlighting their muscular pathways/targets (Erriquez 
et al., 2013; Ge and Chen, 2011).  
It is therefore not surprising that their deregulation heavily contributes to the degeneration of 
dystrophic muscles. For example muscle specific myomiR miR-1 and miR-133 and the ubiquitous 
miR-29c and miR-30c are down-regulated in mdx mice. It is possible to rescue wild-type levels of 
these miRNAs by treating animals with an exon-skipping approach. The same results are confirmed 
also in human DMD samples. These findings corroborate the direct correlation between miRNAs 
levels and dystrophin protein levels. An interesting target of muscle specific miR-133b and miR-
206 is Utrophin (Utrn), a Dystrophin protein homolog, involved in a compensatory mechanism in 
DMD pathology (Basu et al., 2011; Cacchiarelli et al., 2010; Rosenberg et al., 2006). Notably, the 
non-muscle specific miR-31 exert its repressing activity directly targeting the 3'UTR of dystrophin 
transcript to regulate muscle terminal differentiation. miR-31, as well as miR-206, has a preferential 
localization in regenerating myoblasts, and is highly expressed in Duchenne muscles, probably due 
to an intensified activation of satellite cells. In both human and murine wild-type conditions its 
expression is detected in early phases of myoblast differentiation, supporting the idea that it 
contributes to avoid early expression of late differentiation markers. Its de-regulation is thought 
linked to the delay in the maturation program occurring in the DMD pathological context 
(Cacchiarelli et al., 2011a; Durbeej and Campbell, 2002). 
Although the lncRNAs category is less explored than miRNAs one, in general, the biological 
relevance of the lncRNAs is supported by the fact that they are regulated during development and 
involved in almost all levels of gene expression and cellular functions, including chromosomal 
dosage compensation, chromatin modification, cell cycle regulation, control of imprinting, 
alternative splicing, intracellular trafficking, cellular differentiation, and reprogramming of stem 
cells (Li et al., 2013). Recently, lines of evidence linking lncRNAs to muscle are emerging both in 
physiological and pathological context, as well.  
Key features of dystrophic muscle include central nuclei, small regenerating fibers and 
accumulation of connective tissue and fatty tissue. Muscle differentiation in vitro is a useful system 
to investigate the activity of long non-coding RNAs that show muscular specific pattern of 
expression. A new regulatory network involving cross-talk between several ncRNAs has been 
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identified by Cesana and colleagues. Relying on ability of myomiRs to orchestrate muscular 
proliferation and differentiation, the genomic region of miR-206/-133b has been analyzed in detail. 
Thus a novel muscle specific long non coding transcript has been identified. Because of its non-
coding potential and its activated expression upon myoblast differentiation it was termed linc-MD1. 
More specifically, linc-MD1 is expressed in newly regenerating fibers and is abundant in dystrophic 
condition, however no expression is detected in mature differentiated fibers. linc-MD1 is localized 
in the cytoplasm and is a polyadenylated transcript. Through a series of functional studies it has 
been defined as competing endogenous RNA (ceRNA). linc-MD1 acts as a natural decoy for miR-
133 and -135, thus interfering with miRNA repressing activity on the important targets involved in 
myogenic differentiation MAML1(Mastermind-like 1) and MEF2, respectively (Cesana et al., 
2011). 
The deeply studied lncRNA Malat1 (Metastasis associated lung adenocarcinoma transcript 1) is 
another example belonging to this new class of transcripts and linked to muscle biology. Metastasis 
associated lung adenocarcinoma transcript 1 (Malat1) is a highly conserved 8.7 kb non-coding 
transcript that is abundantly expressed in cancer cells and a strong predictor of metastasis . Malat1 
has been proposed to regulate alternative splicing (Tripathi et al., 2010; Wilusz et al., 2012), 
transcriptional activation and the expression of nearby genes (Gutschner et al., 2013). Numerous 
experimental examples support its functional role in the regulation of cell growth, but the exact 
mechanism of action of Malat1 in different physiological and pathological conditions still needs to 
be elucidated. By a microarray data analysis obtained using skeletal muscle of mice (gastrocnemius 
muscle) treated with recombinant myostatin it was observed that the Malat1 expression levels are 
significantly decreased. Myostatin is a potent negative regulator of myogenesis that inhibits 
myoblast proliferation and differentiation (Langley et al., 2002; Zhang et al., 2012). Further 
expression analysis confirmed a persistent up-regulation of Malat1 during the differentiation of 
myoblasts into myotubes in C2C12 cells as well as in primary human skeletal muscle cells. 
Conversely, targeted knockdown of Malat1 using siRNA suppressed myoblast proliferation by 
arresting cell growth in the G0/G1 phase. These results reveal Malat1 as a novel downstream target 
of myostatin with a considerable ability to regulate myogenesis. Although Malat1 appears largely 
dispensable for normal mouse development, it is plausible that Malat1 has a role in the transition 
from the proliferative phase to differentiation in skeletal myogenesis, as well as in the commitment 
to muscle differentiation (Eißmann et al., 2012; Watts et al., 2013). 
Many other lncRNAs have been discovered but not yet fully characterized, as for example Men ε/β 
lncRNAs. To date it is known that two long non-coding isoforms (Men ε/β lncRNAs) which are 
expressed in several human tissues, including muscle, arise from the Multiple Endocrine Neoplasia 
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I locus (MEN1). Experimental lines of evidence show their up-regulation upon differentiation of 
C2C12 myoblats, although their biological role in muscular development is not yet clear. Men ε 
(also known as NEAT1) and Men β are transcribed from the same RNA polymerase II promoter 
and are both retained in the nucleus. Suwoo and colleagues formally demonstrated that Men ε/β 
transcripts are critical structural/organizational components of paraspeckles, organelles localized in 
the nucleoplasm close to nuclear speckles, where RNA-binding proteins and Cat2-transcribed 
nuclear RNA (CTN-RNA) are stored. Moreover, large-scale analysis revealed that many other 
lncRNAs are differentially expressed in C2C12 cells upon myoblast differentiation into myotubes, 
although their biological functions have not been investigated (Clemson et al., 2009; Hubé et al., 
2011; Sasaki et al., 2009).  
Among many functions ascribed to lncRNAs, there are examples of lncRNAs modulating the 
activity of transcriptional activators or co-activators, directly or through the regulation of their sub-
cellular localization (Li et al., 2013). Two of these have been seen also in a muscular context. The 
steroid receptor RNA activator (SRA) RNA is a very peculiar transcript that exists as both non-
coding and coding RNA (yielding SRA ncRNA and protein SRAP respectively). The SRA ncRNA 
is highly expressed in skeletal muscle and works as a co-activator of MYOD transcription factor, a 
master regulator of skeletal myogenesis. To address the significance of the enigmatic bi-functional 
property of this transcript, Hube and colleagues performed an exhaustive analysis clarifying the 
opposite function of non-protein coding SRA versus ORF-containing transcripts. The balance 
between coding and non-coding SRA isoforms changes during myogenic differentiation in primary 
human cells. In particular it is shown that an increased expression of SRA ncRNA and a parallel 
decrease of protein SRAP occurs during myogenic differentiation in healthy muscle satellite cells. 
This does not happen in cells isolated from DM1 patients (Myotonic dystrophy type 1), probably 
because of a delay in the differentiation program. Remarkably, only the ncRNA species enhances 
MYOD transcriptional activity. The protein SRAP prevents this SRA RNA-dependent co-activation 
through interaction with its RNA counterpart. However how this is achieved is not known (Caretti 
et al., 2007; Caretti et al., 2006).  
Non-coding repressor of NFAT (NRON) is another case of lncRNA that shows a regulatory activity 
on a transcription factor. NRON is not highly expressed but it has a distinct tissue specific 
expression. It has been found enriched in placenta, muscle, and lymphoid tissues. NFAT is a 
transcription factor responsive to local changes in calcium signals. It is essential for the T cell 
receptor–mediated immune response and plays a critical role in the development of heart and 
vasculature, musculature, and nervous tissue. The first study about the role of NRON showed that it 
regulates NFAT’s subcellular localization rather than its transcriptional activity. Sharma and 
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coworkers confirmed these data demonstrating that NRON takes part in a large cytoplasmic RNA-
protein complex that acts as a scaffold for NFAT to modulate its nuclear trafficking and thus its 
response activity (Sharma et al., 2011; Willingham et al., 2005). 
DBT-E is an example of lncRNA recently discovered within a pathological muscular context and  
that evidences how this type of non-coding  RNAs might gain a functional role when an altered 
chromatin status exists. Among the many lncRNAs interacting with chromatin remodeling enzymes 
the most famous are Xist and HOTAIR, both acting as a negative regulators of gene expression by 
recruitment of PRC2 (Polycomb Repressive Complex 2) on PcG target genes (Lee, 2009; Rinn et 
al., 2007). Polycomb (PcG) and Trithorax (TrxG) group proteins antagonistically act in the 
epigenetic regulation of gene expression. Typically, TrxG counteracts PcG-mediated epigenetic 
gene silencing.  Cabianca et al. were the first to discover an lncRNA interacting with the TrxG in 
the Facioscapulohumeral muscular dystrophy (FSHD, omim 158900). FSHD is an autosomal-
dominant disease characterized by progressive wasting of facial, upper arm, and shoulder girdle 
muscles. In up to 95% of cases, the genetic defect is mapped to the subtelomeric region of 
chromosome 4q35 containing a macrosatellite tandem array of 3.3 Kb long D4Z4 repeats. FSHD is 
caused by deletions reducing copy number of D4Z4 below 11 units rather than a classical mutation 
in a coding-protein gene. D4Z4 deletion is associated with a loss of repressive epigenetic marks that 
switches from a heterochromatic/close state to a more euchromatic/open conformation of the 
chromatin structure. A novel long non-coding RNA, named DBT-E is produced selectively in 
FSHD patients. DBT-E is transcribed from D4Z4 repeats and it is a chromatin-associated lncRNA 
that coordinates de-repression of genes located in the 4q35 region. DBT-E recruits the Trithorax 
group protein Ash1L to the FSHD locus driving histone H3 lysine dimethylation and thus 
chromatin remodeling (Cabianca et al., 2012).  
According to these lines of evidence, it would be reasonable to think that the complex regulation of 
dystrophin expression is carried out by a combined activity of transcription factors and lncRNAs 
(Erriquez et al., 2013).  
 
Dynamics of Transcription and Co-Transcriptional Processes: an Overview 
 
To transcribe the entire 14 Kb muscle dystrophin mRNA, Pol II acts throughout at least four 
internal promoter regions where many other regulative factors are bound to. In addition, Pol II 
elongation can be impeded in response to repressive chromatin structures (Saint-André et al., 2011; 
Shukla et al., 2011). As a further complication, Pol II elongation does not occur on a barrier free 
linear template (Larson et al., 2011; Selth et al., 2010). To achieve a efficient elongation, 
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nucleosomes are displaced in front of elongating Pol II and reformed in its wake in a process that is 
dependent on elongation rate (Bintu et al., 2011; Kristjuhan and Svejstrup, 2004; Schwabish and 
Struhl, 2004).  
The mechanism to accomplish such remarkable task along the DMD locus is still completely 
unknown. Many open questions are arisen regarding this matter such as the processivity of the 
enzyme, the biochemical composition of Pol II along with associated auxiliary factors involved in 
the transcriptional regulation of the DMD locus, and how it coordinates mRNA synthesis with the 
splicing machinery and with the mRNA-export. Additionally, never has been investigated the 
chromatin context in which Pol II works to transcribe a gene containing 79 exons spread over 2.4 
Mb of DNA. It would be very important to define how Pol II interacts with chromatin components 
and the chromatin regulatory enzymes over a journey 16 hours long. 
A plethora of studies put in evidence that the transcription elongation rate and specific chromatin 
modifications contribute to splice site recognition during transcript processing. Rather than 
operating independently, these processes are tightly integrated to promote co-transcriptional pre-
mRNA splicing. Surprisingly, pre-mRNA splicing reciprocally influence Pol II elongation rate and 
chromatin structure, as well. The idea that arise is that these mechanisms fine-regulate each other 
and  for this reason they should be examined together to provide a more detailed status on 
transcriptional regulation of a specific gene of interest (Shukla and Oberdoerffer, 2012).  
Chromatin modifications either facilitate or hinder access of the DNA to regulate transcription 
expression. The basic unit of chromatin consists of an octamer of four core histones (H2A, H2B, H3 
and H4) wrapped around 146 bp of DNA. Particularly histones H3 and H4 are subjected  to post-
translational modifications including methylation and acetylation and many of these characteristic 
patterns of modification are associated with distinct transcription states. Two important markers of 
open chromatin, histone H3-acetylation (H3ac) and methylation of lysine 4 on histone H3 
(H3K4me),  could be fundamental features to be considered within a so huge DNA locus like that 
DMD gene. Deletion mutations either could influence the overall chromatin epigenetic marks of the 
surrounding regions or remove important chromatin regions that preserve a status of DNA 
permissive to transcription (Eberharter and Becker, 2002; Yan and Boyd, 2006).  
H3K36 methylation  is considered a hallmark of transcribed DNA as well, although it has been 
associated  with several significance and its role nowadays is not completely clear.  
Cotranscriptional methylation of H3K36 by the SET2 family of methyltransferases has been 
implicated in control of transcription elongation, alternative splicing, and mRNA export. Several 
investigations have implicated H3K36me3 in alternative splice site choice. Notably, in a "splicing-
affects-chromatin model"  it seems that the splicing is necessary for establishment and/or 
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maintenance of normal patterns of H3K36 trimethylation. Intriguingly, intronless genes show lower 
levels of H3K36me3 as compared to intron-containing genes, irrespective of their expression status 
(de Almeida et al., 2011; Kim et al., 2011; Sims and Reinberg, 2009). 
Variation in patterns of methylations and acetylation of histone tails reflects and modulates 
chromatin structure and function. Importantly, the post-translational, covalent modifications 
(PTMs) of histones  are tightly coupled to Pol II and, particularly, to its major carboxil-terminal 
modifications. Rpb1, the largest Pol II subunit, contains a highly flexible structure at its C-terminus. 
The carboxil-terminal domain (CTD) consists of tandem repeats with a consensus sequences of 7 
amino acids (Tyr-Ser-Pro-Thr-Ser-Pro-Ser). The number of repeats varies from 26 (all consensus) 
repeats in yeast to 52 (21 consensus and 31 non-consensus) repeats in the mammalian CTD. CTD 
modification plays a direct role in coupling transcription with co-transcriptional nuclear processes 
such as chromatin modification, mRNA splicing and mRNA export. CTD modification undergoes 
changes during transcription to recruit factors at the appropriate point of transcription cycle. 
Dynamic phosphorylation of serine residues on CTD heptad repeats is associated with the stages of 
Pol II elongation. Phospho-Ser 5 peaks near promoters and declines when the Pol II moves along 
the gene. In contrast, Phospho-Ser 2 gradually increases with the distance from the promoter.  
The carboxil-terminal tail of Pol II is thought as a platform that ensures the correct processing 
factors recruitment at the appropriate phase of transcription process to coordinate the chromatin 
remodeling during mRNA synthesis as well as the processing of the nascent transcript. The "CTD 
code" guarantees the specificity of interactions between the factors involved in all these events, as 
by direct than by indirect mechanisms (Egloff et al., 2012). 
It was demonstrated that phosphorylation of Pol II CTD on serine 5 results in recruitment of the 
yeast histone methyltransferase Set1, which subsequently directs methylation of H3K4 (Ng et al., 
2003). Trimethylation of H3K4 peaks at promoters, whereas dimethylation extends into the 5’ 
region of coding regions and monomethylation persists throughout the gene. The pattern of H3K36 
methylation shows a reverse gradient relative to K4, wherein trimethylation increases towards the 3’ 
ends of genes (Barski et al., 2007; Heintzman et al., 2007). According to these lines of evidence 
about the distribution of chromatin markers, the histone 3 K36 methyltransferase, Set2, binds to Pol 
II phosphorylated on serine 2 (Li et al., 2003). 
The Neugebauer laboratory isolated chromatin associated RNA to show that Pol II pauses within 
terminal exons allowing sufficient time for intron excision prior to transcript release (Carrillo 
Oesterreich et al., 2010). Similarly, the Beggs laboratory utilized a high-resolution splicing reporter 
system to demonstrate splicing dependent Pol II pausing at the 3’ ends of introns coincident with 
splicing factor recruitment (Alexander et al., 2010).  Based on these experimental data, intriguingly, 
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both the H3K36me3 and phospho Ser-2 marks seem linked to a kinetic regulation of co-
transcriptional splicing, at least in yeast. Furthermore, these studies raise the question whether Pol II 
pausing represents a splicing “checkpoint” and, since H3K36me3 mark is strongly associated with 
splicing, whether H3K36me3 is correlated to this phenomena. 
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Results 
 
DMD-GEx Microarray Data Analysis 
 
To explore the possibility that long non coding RNAs might be transcribed within DMD locus the 
entire gene was been interrogated in both orientation (sense and antisense) through the design of 
two novel customised DMD specific gene-expression tiling array (DMD-Gex). 
Two independent hybridisation experiments were performed with both the DMD-GEx Sense and 
Antisense microarrays, using poly A+ RNA from human normal brain, heart, skeletal muscle and 
skin. To attest the reliability of the hybridization reaction a control of probe set (Table S1) were 
assayed as well and the chosen control genes displayed an expression profile in agreement with the 
expected orientation and tissue distribution. 
Data were normalized in accordance with the Agilent Quality Controls probes (Spike-in) (see 
Methods and as reported in the link 
http://www.chem.agilent.com/library/usermanuals/public/g4140-90041_one-color_tecan.pdf). 
Values higher than the fluorescence intensity corresponding to 90%  of all ranked probes (90th 
percentile ) on the array were considered as positive hybridization signals. Analysis of both DMD-
GEx Sense and Antisense arrays data allowed to identify as statistically significant a total of 14 
poly-adenylated transcripts which were named according to their intron of origin and orientation 
relative to DMD gene transcriptional direction (Figure 1B). 
As it will be described below none of them contained ORFs encoding protein longer than 100 
amino acids and thereby they were all considered non-coding RNAs (ncRNAs). Twelve of these 
ncRNAs, originating from introns 1 M (2 transcripts), 1P, 2, 29, 32, 37, 44 (2 transcripts), 51, 55 
and 67, were found to be transcribed in the same orientation as the DMD gene. One ncRNA was 
found to correspond to the terminal exon and the 3'UTR of the Dp40 isoform (NCBI: 
NM_004019.2), a known coding dystrophin isoform. The remaining two ncRNAs, originating from 
intron 55 (ncINT55as) and from 3' UTR (nc3UTRas), were found to be transcribed in antisense 
orientation to the DMD gene. A significant proportion of the identified ncRNAs arose from introns 
harboring dystrophin isoform promoters or flanking isoform-specific first exon. In particular, three 
ncRNAs (ncINT1Ms, ncINT1Ms2 and ncINT1Ps) originated from  intron 1 of the Dp427m and 
Dp427p full-length isoforms, one (ncINT29s) from intron 29 (Dp260), two (ncINT44s and 
ncINT44s2) from intron 44 (Dp140) and two (ncINT55s and ncINT55as) from intron 55 (Dp116). 
All identified transcripts were strongly expressed in at least one of the three tissues known to 
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express large amounts of dystrophin. A significant proportion of them were shown to be present in 
either the skeletal muscle (85.71%) or the heart (71.43%), and nine transcripts were identified in 
both tissues. Five ncRNAs were found in brain tissue, one of which (ncINT37s) was uniquely 
expressed in this district  (Table 1) (Bovolenta et al., 2012a). 
 
Figure 1. Example of transcripts (ncINT1Ms2) identified by the DMD-GEx array. A) a series of consecutive probes in the genome with fluorescence 
intensities that rank above the 90th percentile over all probes on the array (indicated with a dashed red line) and mapping within intron 1 M 
(chrX:33057364-33059742). B) location of the transcripts identified from poly A+ RNA with respect to the DMD gene isoforms. Sense transcripts are 
represented by blue bars, whereas antisense transcripts are indicated by green bars. The transcripts marked with an asterisk and a double cross were 
characterized by Northern blotting, and RACE PCR. (doi:10.1371/journal.pone.0045328.g001)  
 
Transcript Validation by Northern Blot Analysis 
 
To confirm and determine in a more detailed manner the pattern of expression of the identified 
transcripts as well as their precise size and relative amount, northern blotting analyses were 
performed. ncRNAs whose location within the DMD gene suggested a possible regulatory role in 
the expression of the many DMD gene isoforms were preferentially chosen. Nine poly A+ sense 
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ncRNAs mapping in proximity to the DMD gene promoters or nearby isoform first exons, and two 
antisense transcripts, mapping at the 3' end of the DMD locus were selected. 
The probes identifying transcripts ncINT1Ms1, ncINT1Ps and ncINT29s revealed complex patterns 
of hybridisation, consisting of multiple bands or a smeared signal, in several tissue. The difficulty to 
obtain defined and clear bands is the reason for which we decided to not longer study these 
ncRNAs. 
 
 
Table 1: Genomic location, length and tissue representation of the human transcripts identified. (doi:10.1371/journal.pone.0045328.t002) 
 
On the contrary, Northern blotting results obtained for other four sense transcripts (ncINT1Ms2, 
ncINT44s, ncINT44s2 and ncINT55s) and two antisense transcripts (ncINT55as and nc3UTRas) 
revealed several distinct transcripts ranging from 1.4 to 4 kb in length and confirm their expression 
in at least one of the three tissues in which dystrophin is normally expressed (skeletal muscle 
(SkM), heart and brain) reflecting that observed in the array (Figure 2). (ncINT1Ms2, ncINT44s, 
ncINT44s2 and ncINT55as: SkM and heart; ncINT55s and nc3UTRas: SkM, heart and brain).  
Notably, the ncINT1Ms2, ncINT44s2, ncINT55as and nc3UTRas were highly represented in the 
heart tissue, whereas the ncINT44s and ncINT55s were found to be more intensively transcribed in 
skeletal muscle. Furthermore, most transcripts were also detected in the liver, placenta and/or 
kidney (Figure 2). Different tissue-specific isoforms were detected in four transcripts: ncINT1Ms2 
presented at least four isoforms, ranging from about 1.8 to 5 Kb in size. A 2.4 Kb form is prevalent 
in the heart and liver, whereas it is poorly represented in the skeletal muscle and kidney; two 
ncINT44s2 isoforms were found in the skeletal muscle tissue, while only the larger one (about 2.7 
kb) was detectable in the heart; ncINT55s was detectable in the heart and SkM in at least three 
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different isoforms (from 2.4 to 3 Kb), showing a specular pattern of expression in the two tissues. 
The larger of these isoforms was also found to be present in the kidney and placenta. An additional 
isoform of about 5 Kb is present exclusively in the brain. nc3UTRas show at least two isoforms (1.5 
kb and 1.8 Kb). The larger form is widely represented in all tissues analysed, with the exception of 
the thymus and colon while both isoforms show a preferential expression in placenta, liver and heart 
(Figure 2). Only one form of transcript has been detected for ncINT44s and ncINT55as. ncINT44s 
is roughly 2.4 Kb in size and is expressed almost exclusively in the heart and skeletal muscle, being 
particularly abundant in the latter. In contrast, the ncINT55as transcript is about 2.4 Kb in length 
and displayed widespread distribution, being present in all analysed tissues except the brain and 
muscle (Figure 2) (Bovolenta et al., 2012a). 
 
Figure 2. Northern blotting analyses on a 12-lane human poly A+ RNA filter using probes designed on ncRNAs originating near the first exons of 
DMD isoforms and antisense transcripts. Transcript ncINT1Ms2 is located near full-length DMD gene isoform Dp427p, whereas ncINT44s and 
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ncINT44s2 surround isoform Dp140. Transcripts ncINT55s and ncINT55as are located upstream the Dp116 isoform. Nc3UTRas overlaps with 
39UTR in antisense direction with respect to the DMD gene. All transcripts were expressed in at least one tissue in which DMD isoforms were also 
expressed, but also in the liver, kidney, spleen and placenta. ncINT1Ms2, ncINT44s2, ncINT55s and nc3UTRas were found to be expressed in 
multiple isoforms, while one single isoform was detected for ncINT44s and ncINT55as.(doi:10.1371/journal.pone.0045328.g002) 
 
Full-length Transcript Characterization by RACE PCR 
 
To precisely define the size of the six DMD ncRNAs validated by Northern blotting, 3' and 5'-
RACE analyses were performed on poly A+ RNA. 
ncINT1Ms2: the products obtained from 3'-RACE, transcript walking and 5'-RACE were sequenced 
and combined, generating a full-length sequence of 2379 bp. The ncRNA was sense-transcribed 
with dystrophin mRNA and was found to be colinear with the dystrophin intron 1 sequence (Figure 
3 A, B and C). The 3' end of the ncINT1Ms2 transcript is located 897 bp upstream of the 5'UTR 
Dp427p full-length dystrophin isoform. 
ncINT44s and ncINT44s2: for ncINT44s, analysis of transcript walking, 3'- and 5'-RACE products 
yielded a full-length 2.6 Kb transcript entirely transcribed from intron 44 that did not undergo 
splicing (Figure 3 B and C). For ncINT44s2, the product obtained from 3'-RACE was combined 
with the two products identified by 5'-RACE, which defined two alternative transcriptional start 
sites (2452-bp and 2718-bp sequences) corresponding to the two full-length isoforms found in the 
Northern blotting experiment. Sequencing analysis revealed that these RNAs were entirely 
transcribed from intron 44, without undergoing splicing events (Figure 3 B and C). The two 
ncRNAs identified within intron 44 are located 29 Kb upstream (ncINT44s) and 61 Kb downstream 
(ncINT44s2) of the Dp140 dystrophin isoform promoter. 
ncINT55s and ncINT55as: for ncINT55s, 3'-RACE identified two different 3' ends. After transcript 
walking, 5'-RACE gave rise to two distinct PCR products corresponding to different transcriptional 
start sites (Figure 3 A). Nucleotide sequence analysis revealed that these transcripts originated 
entirely from intron 55, without splicing events (Figure 3 A, B and C). Combination of these start 
and polyadenylation sites potentially generates at least four transcripts of 2805, 2720, 2513 and 
2428 bp, which is consistent with the Northern blotting data. The ncINT55as is transcribed in an 
antisense direction with respect to transcription of the dystrophin gene. 3'-RACE identified two 
different 3' ends, and 5'-RACE detected three isoforms with a common 5' end (Figure 3 A). 
Interestingly, these transcripts are alternatively spliced, generating RNAs of different sizes. A 
shorter isoform carrying only the common 3' and 5' ends was also identified (Figure 3 B and C). 
The predicted molecular weight of the three different isoforms ranges from 2642 bp to 2732 bp, 
being consistent with a single product detectable by Northern Blotting analysis. Notably, ncINT55s 
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residues within that DNA region is a part of the largest "intron" of the mature ncINT55as RNA 
isoforms. All of these different transcripts identified within intron 55 are located roughly 55 Kb 
upstream of the Dp116 promoter. 
nc3UTRas: sequence analysis of the 3' and 5'-RACE products gave a full-length 1872-bp transcript 
transcribed in an antisense direction from the 3'UTR region of the DMD gene. Since splicing events 
were not observed (Figure 3 A, B and C), this transcript overlaps (in an antisense orientation) 
roughly 2 Kb of the 3'UTR region of all full-length and 3'UTR region of all shorter dystrophin 
isoforms (Bovolenta et al., 2012a). 
 
 
 
Figure 3. Full-length transcript characterisation by RACE PCR. A) For transcript ncINT1Ms2, a single product of 370 bp was obtained with 3'-
RACE. After transcript walking, 5'-RACE was performed and identified a 396-bp PCR product. ncINT44s 3'-RACE generated a single product of 423 
bp. After transcript walking, PCR, 5'-end was identified by 5'-RACE, and gave rise to a 599-bp PCR product. For transcript ncINT44s2, a single 
product of 552 bp was obtained by performing 3'-RACE, whereas 5'-RACE originated two distinct PCR products of 328 bp and 689 bp, 
corresponding to different transcriptional start sites. 3'-RACE of transcript ncINT55s revealed two products, of 150 bp and 442 bp, corresponding to 
different 3' ends of the transcript whereas 5'-RACE gave rise to two distinct PCR products of 673 bp and 352 bp. NcINT55as analysis by 3'-RACE 
identified two PCR products of 99 and 431 bp, corresponding to different 3' ends. 5'-RACE identified three PCR products of 307, 343 and 398 bp. 
Both 3' and 5'-RACE PCR products for transcripts nc3UTRas showed unique bands of 99 bp and 286 bp, respectively. Relevant pairs of primers used 
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are listed below each image. B) Schematic representations of the RACE PCR results for transcripts ncINT1Ms2, ncINT44s, ncINT44s2, ncINT55s, 
ncINT55as and nc3UTRas. Transcript orientation is indicated by the zigzag arrows. Their position with respect to adjacent dystrophin exons and 
isoform promoters is shown. DMD gene exons are shown as vertical red boxes, and 5' and 3' UTRs as horizontal red boxes. Lighter colours within the 
transcripts ncINT44s2, ncINT55s and ncINT55as boxes represent alternative starting or polyadenylation sites. The three alternative spliced isoforms 
of transcript ncINT55as are represented. C) Sequences of the identified transcripts are shown with reference to human genome build 18 (hg18, March 
2006). Donor and acceptor splice sites are highlighted in yellow for transcript ncINT55as. Polyadenylation sites are underlined in the sequences. 
Curved arrows show the starting site for transcription of non-coding transcripts. (doi:10.1371/journal.pone.0045328.g003) 
 
Bioinformatics Analysis of Coding Potential and Secondary Structure 
 
Using bioinformatic tools the six novel transcripts were tested for coding potential, ability to fold 
into secondary structures and for their degree of conservation.  
To confirm that the ncRNAs did not possess the potential to encode for polypeptides, ORF-Finder 
software was employed to predict putative ORFs with a minimal length of 100 amino acids. As 
shown in Figure 4A, none of the three sense-frames contained any ORF fitting those criteria. The 
same results were obtained using the CPC tool, which identified a weak coding potential (one ORF 
of 51 amino acids) for the ncINT1Ms2 (Figure S2). CPC also analysed homology with UTR 
regions, and found 37 and 35 hits for ncINT1Ms2 and ncINT55as, respectively. 
Using Mfold software, we also determined whether these transcripts could fold into higher 
secondary structures typical of non-coding RNAs. Interestingly all six ncRNAs can fold into 
secondary structures with a ΔG below -50 Kcals (Figure 4 B), thereby suggesting that these 
structure may be extremely stable and likely to serve as domains for interaction with other cellular 
components.  
Conservation analysis performed using the UCSC Genome Browser (UCSC Genome Browser 
website. Available: http://genome.ucsc.edu/) showed that all identified transcripts are poorly 
conserved, with the exception of nc3UTRas, which is transcribed from the 3'UTR of the DMD 
gene, and transcript ncINT1Ms2, which presents a highly conserved sequence of roughly 130 bp. 
The UCSC Genome Browser was also employed to check for the presence of any known ESTs or 
mRNAs overlapping DMD ncRNAs. For some of the ncRNAs identified, predominantly small tags 
intersecting their sequences were detected: ncINT1Ms was found to overlap with part of a wider 
mRNA found in the uterus (Ota et al., 2004); ncINT1Ms2 contained two smaller ESTs found by 
Robertson et al. (Robertson et al., 1994) in 16-22-week foetal cochleas; ncINT1P overlapped 
several ESTs previously described (NCBI-CGAP website. Availble: 
http://www.ncbi.nlm.nih.gov/ncicgap.; NIH-MGC website. Available: http://mgc.nci.nih.gov/.) and 
corresponds to the TBCAP1 pseudogene (ENST00000436520); ncINT32s was found to contain a 9 
bp Gallus Gallus DMD exon; and ncINT44s and ncINT55s, respectively, overlapped two smaller 
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ESTs identified in neuroblastoma tissues (Ohira et al., 2003). No tRNAs were detected within the 
sequences of the ncRNAs identified (data not shown) (Bovolenta et al., 2012a). 
ncRNA Expression Profiles Mirror those of Full-length Muscle and Brain 
Dystrophin Isoforms 
 
To understand whether the ncRNA expression might be functionally associated with that of 
dystrophin, we compared the expression of the validated ncRNAs and dystrophin isoforms in six 
different human cell lines. Three cell lines HEK-293, HeLa and p493 were chosen for the absence 
of expression of the muscle and brain dystrophin isoforms, although they express low levels of the 
Purkinje isoform and moderate-good levels of the Dp71 ubiquitous isoform, (Fig. 5A left). In 
contrast, the SHSY5Y neuroblastoma cell line and, in particular, the two rhabdomyosarcoma cell 
lines (RD and SJCRH30) were chosen for their good expression of the muscle and brain dystrophin 
isoforms (Fig. 5A, right). Expression of five ncRNAs was monitored in the cell lines by qRT-PCR. 
Instead, nc3UTRas was not included in this part of the study since analysis could have been 
complicated by the fact that it overlaps the 3'UTR region of all full-length and all shorter 3'UTR 
dystrophin isoforms. Expression of each ncRNA was calculated as the ratio between expression of 
the ncRNA in a given cell line and that in HeLa cells, which were found to have the lowest level of 
transcription of all tested ncRNAs. As shown in Fig. 5B, expression of the five ncRNAs is several 
orders of magnitude higher in cells displaying good levels of full-length muscle and brain 
dystrophin isoforms than in the other cell lines, thereby suggesting that ncRNAs and dystrophin 
expression may follow similar dynamics. To further support this idea, we determined the expression 
levels of our ncRNAs in human normal fibroblasts and human fibroblasts previously transformed 
with MyoD, a well recognised master transcription regulator that can induce fibroblasts to undergo 
myogenesis. Results show that MyoD-transformed fibroblasts present strong expression of all tested 
ncRNAs, as compared to untransformed fibroblasts, which parallels the expression of full-length 
muscle and brain DMD isoforms (Bovolenta et al., 2012a). 
 
DMD lncRNAs are Confined to the Nuclear Compartment 
 
To further explore whether analysed ncRNAs may be functionally linked to the expression 
dynamics of the DMD locus, their intracellular distribution was determined. GAPDH mRNA was 
used as a fractionation control, since it is known to be restricted to the cytoplasm. Results show that 
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all tested ncRNAs are essentially nuclear (Fig. 6), suggesting that expression of the ncRNAs may be 
important for the transcriptional architecture of the DMD locus (Bovolenta et al., 2012a).  
 
 
 
 
Figure 4. Coding potential and secondary structure bioinformatics analysis. A) ORF prediction. The on-line tool ORF Finder was used to detect open 
reading frames in our lncRNAs. ORFs identified by the programme are shown in green. Each grey line represents the reading frame, divided into 
sense (first three lines) and antisense (fourth to sixth lines) strands. The length, reading frame, nucleotide start and end position of each ORF are listed 
on the right of each transcript; B) Mfold analysis of the secondary structure of the lncRNAs characterised: Mfold software showed that all six 
lncRNAs were able fold into secondary structures with negative DG below 250 kcals, indicating the great stability of these 
structures.(doi:10.1371/journal.pone.0045328.g004) 
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Figure 5. Expression of lncRNA correlates with that of full-length dystrophin isoforms. A) Standard RT-PCR of various dystrophin isoforms in six 
different human cell lines: HEK-293 (embryo kidney), HeLa (epithelial cervical cancer) p493 (lymphoblastoid), SH-SY5Y (neuroblastoma), RD 
(rhabdomyosarcoma) SJCRH30 (rhabdomyosarcoma), B) Expression of ncRNA in different cell lines determined by qRT-PCR. HeLa cells were 
chosen as reference cells since expression of lncRNAs in those cells was the lowest detected. Therefore, expression of lncRNAs in other cell lines was 
compared to that of HeLa cells, which was set to 1. Fold difference is expressed as Log10 of the ratio. Data represent the average of three independent 
experiments performed in triplicate. Standard error deviation is shown. C) Expression of dystrophin isoforms in human normal fibroblast (CTRL) and 
fibroblasts transformed with MyoD as determined by standard RT-PCR. D) Relative expression of lncRNA in MyoD fibroblasts (MyoD), as 
compared to that of untransformed fibroblasts (control, CTRL), which was set to 1. Data are the average of three independent experiments performed 
in triplicate. Standard error deviation is shown. (doi:10.1371/journal.pone.0045328.g005) 
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Figure 6. Intracellular localization of lncRNAs in three distinct human cell lines. Cytoplasmic and nuclear fractions of cellular RNA were analysed 
for lncRNA expression by qRT-PCR. Cyt = Cytoplasm, Nuc = Nuclear. qRT-PCR was performed for more than 50 cycles in order to detect even 
extremely low transcript levels. When expression was detected just in one compartment, the relative quantity of a given lncRNA was set to 1, 
indicating that 100% of the transcript was observed only in that compartment. In contrast, when both compartments expressed some levels of the 
lncRNA, distribution of the transcript between the two compartments was quantified as a relative percentage. In the specific case, standard error 
deviation was calculated. Quality of extracted RNAs was evaluated by running 1 ug of nuclear and cytoplasmic RNAs on a denaturing agarose gel. 
28S and 18S ribosomal RNA are indicated as molecular weight markers. (doi:10.1371/journal.pone.0045328.g006) 
 
Sense ncRNAs Negatively Modulate Dp427m, Dp427b and Dp427p Isoforms but 
not Dp71 
 
To investigate the function of our long ncRNAs, we reasoned that similarly to other long ncRNAs 
function, DMD ncRNAs may act to regulate the expression of the dystrophin transcription. To test 
this hypothesis, we initially used RNA interference to deplete the expression of a ncRNAs. 
However, this approach failed, most likely because siRNAs cannot efficiently target nuclear 
transcripts (data not shown). We decided then to adopt an alternative approach through which we 
wished to perturb the endogenous dystrophin expression by exogenous overexpression of the DMD 
lncRNAs. To this purpose ncINT44s, ncINT44s2, ncINT55s and nc3UTRas sequences were cloned 
into the pcDNA3.1(+) expression vector, under the transcriptional control of the CMV promoter. 
Rhabdomyosarcoma (SJCRH30) or neuroblastoma (SH-SY-5Y) cells were individually transfected 
with each ncRNA. As a negative control, cells were also transfected with the pcDNA3.1(+) empty 
vector. Total RNAs were prepared and tested by qRT-PCR for expression levels of endogenous 
dystrophin isoform mRNAs. GraphPad Prism 5 software and one-way ANOVA with Dunnett’s test, 
were used to statistically analyse the mean of RT-PCR results obtained from triplicates of three 
independent experiments performed in each tested cell line. Figure 7 shows that, with the sole 
exception of the nc3UTRas, overexpression of each long non coding transcript results in a 
significant reduction of Dp427m and Dp427b in both cell lines when compared to the control 
sample. Although modest, we could also observe some reduction on the Purkinje dystrophin 
isoform (Dp427p). Importantly, no variation was observed with regard to the Dp71 transcript, 
suggesting that the effect of sense lncRNAs on muscle and brain dystrophin isoforms is specific. 
Overall our finding support a model in which specific DMD lncRNAs can control muscle and brain 
dystrophin isoforms by down-modulating their transcription level. Finally to understand how 
lncRNAs can affect dytrophin transcription we have analysed their effect on a luciferase reporter 
gene whose expression is driven by the Dp427m promoter. A SV40-luc reporter was also used as a 
negative control. The analysis was performed both in SH-SY5Y human cells and in mouse C2C12 
undifferentiated myoblasts. Figure 8 shows that all three lncRNAs can significantly down-regulate 
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expression of the Dp427m-Luc reporter but not that of the SV40-luc reporter, thus supporting the 
model that DMD lncRNAs can negatively control muscle specific dystrophin isoform expression by 
targeting the promoter (Bovolenta et al., 2012a). 
 
Figure 7. Overexpression of individual lncRNAs downregulates muscle and brain dystrophin mRNA isoform expression. SJCRH30 (panel A) and 
SH-SY-5Y (panel B) cells were separately transfected with vectors expressing ncINT44s, ncINT44s2, ncINT55s, nc3UTRas respectively. 
Endogenous expression of Dp427b, Dp427m, Dp427p and Dp71 dystrophin mRNA isoforms was determined by qRT-PCR with specific TaqMan 
systems. The pcDNA3.1(+) empty vector was used as a negative control. Amount of each dystrophin isoform was normalized to ß-actin mRNA, and 
was expressed as 2-DDCt. Dystrophin expression levels determined for each ncRNA transfection were compared to the condition with the empty 
vector which was set to 1. Statistical analyses were performed using one-way ANOVA with Dunnett’s test based on results of three indepedendent 
transfections in which each transfection point was performed in triplicate. The error bars and asterisks represent the standard deviations and p-values 
respectively. (*) = p,0.05; (**) p,= 0.01; (***) = p,0.001, ns = non significant. doi:10.1371/journal.pone.0045328.g007 
 
Relative Expression of lncRNAs and Dystrophin Isoforms in Muscles of DMD 
Female Carriers 
 
To support the idea that a negative relationship between lncRNAs and dystrophyn mRNA levels 
may exist, we analysed expression of lncRNAs in muscle samples of 9 DMD female carriers either 
healthy or mildly affected (Table 2). Since the relative amount of dystrophin mRNA can be 
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significantly different among samples, the relative amount of each lncRNAs was compared with the 
ratio between dystrophin mRNA and lncRNAs amounts of the same sample. Through this 
mathematical device we should be able to observe whether the two variables (ncRNA and 
dystrophin mRNA) are somehow causally linked or completely independent. As predicted we found 
an inverse correlation between ncRNA expression and dystrophin expression (Fig. 9), thus 
supporting the model of a negative regulation of lncRNAs on specific muscle dystrophin transcripts 
(Bovolenta et al., 2012a). 
 
Figure 8. lncRNAs down-regulate expression of a luciferase reporter driven by the Dp427m promoter. Cartoons describes the Lucreporter construct 
and lncRNAs expression vectors. Expression of the muscle dystrophin reporter was determined as a function of co-transfection of the ncNT44s, 
ncNT442s and ncNT55s RNAs and of the expression vector alone used as the negative control whose activity was arbitrarily set to 1. An SV40-luc 
reporter was used as a control of the specificity of the lncRNA effect. Transfections were performed in human neuroblastoma SH-SY5Y cells 
(drak grey bars) as well as in mouse C2C12 myoblasts (light grey bars). Results are the average of four indipendent trasfection experiments in which 
each point was analysed in triplicate. Statistical significance is indicated by either two or three asterisks representing p-values ,0.01 and 0.001 
respectively. (doi:10.1371/journal.pone.0045328.g008) 
 
 
 
Table 2. Classification and mutations of the Female Carriers. (doi:10.1371/journal.pone.0045328.t001) 
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Figure 9. Correlation between the expression of different dystrophin mRNA isoforms and expression of ncRNAs. Expression of 
individual ncRNAs as well as of distinct dystrophin isoforms was determined in muscle samples obtained from DMD female carriers by qRT-PCR. 
Relative amount of each lncRNA was correlated to the the ratio between dystrophin mRNA amount and lncRNAs amount. In the graph female 
carriers were ordered based on their relative expression of lncRNAs ranging from that with lowest to that with highest lncRNA levels. The same order 
was maintained for dystrophin/lncRNA ratios. (doi:10.1371/journal.pone.0045328.g009) 
 
New Regulative Regions Within Human DMD Locus 
 
An intriguing aspect regarding the transcription of the DMD locus is due to the gene size (2.4 Mb). 
In fact, RNA polymerase II takes about sixteen hours to complete synthesis of the primary transcript 
and how the polymerase can accomplish such a extraordinary task has never been investigated.  
It has been demonstrated that the phosphorylation of specific serine residues on Pol II CTD heptads' 
repeats reflects each specific phase of the transcription cycle. At the initiation of transcription, the 
serine at position 5 (P-Ser5) becomes phosphorylated to permit promoter clearance. As Pol II 
elongates toward the 3' end of the gene Ser5 phosphorylation declines and there is increased 
phosphorylation of serine at position 2 (P-Ser2) which promotes recruitment of the 3' end 
processing factors. 
Importantly, Pol II CTD modifications are functional coupled to processing of pre-mRNA as well 
as to chromatin modification. Trimethylation of H3K4 peaks at promoters, whereas dimethylation 
(2Me-H3K4) extends into the 5’ region of coding regions and monomethylation persists throughout 
the gene. The pattern of H3K36 methylation shows a reverse gradient relative to K4. The 
trimethylation of H3K36 increases towards the 3’ ends of genes and it is functionally associated 
with actively transcribed genes and in particular with splicing process. H3K36me3 exon marking 
provides a dynamic link between transcription and splicing. Finally, H3 acetylation (Ac-H3) 
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represent an important hallmark that define chromatin regions permissive for gene expression and 
in particular localized histone acetylation is observed in promoter and enhancer elelments. 
To explore the entire DMD locus while it is actively transcribed, we performed ChIP-on-chip 
analysis. Specifically, we analyzed the distribution of  RNA polymerase II (Pol II), its CTD 
functional modification, phosphorylation on serine 2 and serine 5 (P-Ser2, P-Ser5) and the major 
histone modifications (Ac-H3, 2Me-H3K4, 3Me-H3K36) associated with the transcription along the 
2.4 Mb spanning the gene. To identify new regulative regions within the DMD locus, ChIP-on-chip 
experiments were carried out in two specific cellular models: the SJCRH30 rhabdomyosarcoma cell 
line, deriving from a male striated muscle tumor, which expresses the two most relevant full-length 
dystrophin isoforms, Dp427b and Dp427m and the Dp71 isoform; the HeLa cells, which instead 
expresses only the ubiquitous Dp71 isoform.  
The immunoprecipitated DNA was amplified by a whole genome PCR method, labeled and 
hybridized onto custom made chip DNA arrays carrying probes corresponding to the single copy 
portion of the DMD locus. Raw data have been processed for statistical significance using the 
Whitehead Per-Array Neighborhood algorithm. 
ChIP-on-chip results obtained from SJCRH30 cells have shown enrichment for those DNA regions 
in close proximity to transcriptional start site (TSS) of Dp427b and Dp427m, as expected. Pol II, P-
Ser2 and P-Ser5 are enriched through the first exon of each isoform while P-Ser2 is enriched along 
the most distal regions.  Their active transcriptional status was demonstrated by showing that the 
some regions were enriched also for the two markers of open chromatin, Ac-H3 and 2Me-H3K4 as 
well. These findings (Fig. 10A) corroborate the accepted model in which  the CTD modifications of  
Pol II are coupled to the stages of transcriptional cycle as well as to post-translation histone 
modifications. When Pol II is hyperphosphorylated only in P-Ser5 it is stalled on the transcriptional 
start site (producing abortive RNAs), whereas, when it became phosphorylated in P-Ser2, Pol II 
switch on to a processive status and catalyzes polymerization of transcripts. 
Furthermore, as we expected, slight enrichment for P-Ser2 and P-Ser5 were been obtained in the 
chromosomal region coding for Dp71 isoform, the ubiquitous expressed dystrophin (Fig.10A). 
None enrichment, instead, were found on Dp427p TSS.  
Surprisingly, the same pattern of enrichments (for Pol II, P-Ser2, P-Ser5, Ac-H3 and 2Me-H3K4) 
were been found in regions that have never been associated before with a transcriptional activity 
within the DMD locus: an intronic region of 3Kb, approximately 21Kb downstream of the end of 
DMD exon 52, and a region of 4Kb, spanning the DMD exon 62 (Fig. 1B). 
The presence of the 3Me-H3K36 mark downstream of the exon 62 region suggests that, here, the 
RNA polymerase could coordinate two important transcriptional processes that are occurring: the 
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recognition of exon 62/63 junction during transcription of two full-length dystrophin isoforms 
(where the Pol II pauses to regulate the splicing events) and the TSS of the Dp71 isoform 
transcription, which is contained within the intron 62. 
Interestingly, we found strong presence of open chromatin marks (Ac-H3 and 2Me-H3K4) around 
intron 34 and the exon 45 of the DMD locus, notably without presence of RNA polymerase II. 
These findings suggest that these DNA regions may exert a regulatory function, possibly acting as 
enhancer-like elements on specific dystrophin promoters (Fig 10C). 
To verify whether Pol II distribution and the pattern of histone H3 methylation and acetylation 
found in rhabdomyosarcoma cell line  could be either correlated to transcriptional dynamics of the 
DMD locus or unrelated to this, the ChIP-on-chip analysis was also performed in HeLa cells. 
Moreover, as we said before, since the DMD locus is regulated in a different manner in the two cell 
lines, comparing the profile of Pol II distribution and chromatin modifications obtained in  both 
cellular contexts allowed us to discriminate which putative regulative regions are involved in 
muscle and brain dystrophin isoforms expression. 
In HeLa cells, the ChIP-on-chip data analysis showed no enrichments of Pol II around the Dp427b, 
Dp427m and Dp427p TSS, while revealed an actively transcribed chromatin around the Dp71 TSS 
region (Pol II, P-Ser2, P-Ser5, Ac-H3 and 2Me-H3K4), as we expected. This result underlines that 
ChIP-on-chip methods is a powerful and reliable experimental approach to disclose the 
transcriptional status of a gene of interest  (Fig 10D). As shown in Figure 10E, RNA polymerase II 
and pan-acetylation of histone 3 signals were not detected from the regions around the intron 52 and 
exon 62. Nonetheless, the 2Me-H3K4 mark was still present on the intron 52 and exon 62. 
Interestingly, distribution of this mark on exon 62 was, however, different from that observed in 
rhabdomyosarcoma cells. Together, these data suggest either that the new possible transcriptional 
start sites could be inactive or that these chromatin regions play other functions  for the DMD locus 
in HeLa cells (Fig. 10E). Finally, contrary to that we found in SJCRH30 cells, the marks of 
transcriptionally active chromatin such as pan-acetylation and 2Me-H3K4 were completely absent 
at the in intron 34 and exon 45 regions (Fig.10F), supporting the hypothesis that these regions are 
specifically involved in muscle and brain dystrophin isoforms expression. 
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Figure 10. Distribution of  RNA polymerase II (Pol II), its CTD functional modification, phosphorylation on serine 2 and serine 5 (P-Ser2, P-Ser5), 
and the major histone modifications associated with the transcription and splicing (Ac-H3, 2Me-H3K4, 3Me-H3K36) along the human DMD locus. 
The enrichment signals found by ChIP-on-chip analyses were displayed. In SJCRH30 cells: A) Dp427b, Dp27m and Dp71 TSS regions showed 
enrichments for Pol II, P-Ser5, P-Ser2, Ac-H3, 2Me-H3K4 and 3Me-H3K36; B) regions surrounding intron 52 and exon 62 were enriched for Pol II, 
P-Ser5, P-Ser2, Ac-H3, 2Me-H3K4. The 3Me-H3K36 mark was found only downstream of exon 62; C) the regions around intron 34 and exon 45 
showed enrichments for the Ac-H3, 2Me-H3K4; In HeLa cells: D) the Dp71 TSS region showed enrichments for Pol II, P-Ser5, P-Ser2, Ac-H3, 2Me-
H3K4 and 3Me-H3K36; E)  the 2Me-H3K4 mark was found around intron 52 and exon 62 regions but it showed a different distribution from that 
observed in rhabdomyosarcoma cells F) no enrichments for Ac-H3, 2Me-H3K4 were found within intron 34 and exon 45 regions. 
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Further Analysis of DMD Intron 52 and Exon 62 Regions 
 
To validate the distribution of RNA polymerase II and its major CTD modifications on the 
previously identified DMD intron 52 and exon 62 regions, qChIP experiments were performed 
using antibodies against Pol II, P-Ser2 and P-Ser5. Several pairs of primers encompassing the DNA 
regions found through the ChIP-on-chip method were designed to define more finely where the 
enzyme shows a stronger signal of occupancy (Fig. 11). Moreover, to discriminate whether the Pol 
II-enriched intron 52 and exon 62 regions are new transcriptional start sites or pausing sites, we 
performed qChIP on SJCRH30 cells after treatment with 5,6-DichloroBenzimidazole Riboside 
(DBR), an RNA polymerase inhibitor which prevents Pol II to switch from the stalled to the 
processive conformation. The rationale is that, after treatment, only the transcriptional start sites 
will be enriched for RNA Polymerase II, while an hypothetical pausing site will be depleted of a 
processive polymerase, in particular of the signal relative to the Pol II modified on CTD serine 2 
residues. As shown in figure 11, we observed a depletion of RNA Polymerase II occupancy on the 
intron 52, suggesting that this region may represent a pausing site for the polymerase during the 
transcription of Dp427m and/or Dp427b mRNAs. Regarding the exon 62 region, instead, the 
enrichments for Pol II and P-Ser5 were still preserved after DRB treatment, but that for the P-Ser2 
was strongly reduced, suggesting that the region may bear a new possible transcriptional start site 
(Fig. 11) on which the polymerase is sitting, however without being processive. This implies that, 
under certain circumstances this region may generate novel RNAs not yet described. As a control 
experiment, we also analyzed the region encompassing the known TSS of GAPDH gene.  Again, 
after DRB treatment  we can observe a dramatic reduction of the P-Ser2 signal (Fig. 11). 
 
Further Analysis of DMD Intron 34 and Exon 45 Regions 
 
To investigate what kind of regulatory function intron 34 and exon 45 regions might exert on the 
brain and muscle dystrophin transcription (i.e. enhancer-like or silencer-like), each DNA region was 
cloned, in both orientation (direct and inverse in respect with transcriptional direction), downstream 
of luciferase gene reporter (Luc ) driven by either Dp427b or Dp427m promoter. The two regions 
were positioned downstream of the reporter gene in order to reflect their original position with 
respect to the dystrophin promoters in the DMD locus.  Each construct was transiently transfected in 
the HeLa and  SJCRH30 and luciferase activity was monitored at 24 hours from transfection. 
Results showed no significant variation in Dp427b promoter activity for both regions (data not 
shown). 
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Surprisingly, the intron 34 and exon 45 regions seem modulate Dp427m promoter (Fig. 12) in both 
tested cell lines. Regarding the first one, it showed the ability to stimulate the Dp427m promoter 
transcription when cloned in both orientation, but preferentially in the inverse orientation with 
respect to transcriptional direction (Fig. 12A). By sequential deletions of the cloned intron 34 region 
it was possible to identify the minimal region required for transcriptional stimulation of Dp427m 
promoter. Such region, deleted in Int 34Δ1 construct, corresponds to chromosomal coordinate 
ChrX: 32389220-32389513 (GRCh37/hg19).  
The region spanning the DMD exon 45 shows a direction dependent behavior; indeed it can 
stimulate the Dp427m promoter only when it is cloned in opposite manner with respect to 
transcriptional direction (Fig. 12B).To identify the minimal region of exon 45 required for Dp427m 
promoter stimulation we proceeded to sequential deletion of the cloned region. Stimulating activity 
was still present in Ex45 InvΔ1 construct while it was lost  in Ex45 InvΔ2 plasmid, suggesting that 
stimulating region is uniquely deleted in Ex45 InvΔ2 and corresponds to chromosomal coordinate 
ChrX: 31986208-31982621 (GRCh37/hg19). Although the luciferase reporter technology does not 
take into account the chromosomal distances between the Dp427m promoter and either intron 34 or 
exon 45 regions, it revealed precious insights about the molecular significance of such DNA 
elements within DMD locus.  
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Figure 11. Validation of DMD intron52 and exon 62 regions were carried out by qChIP experiments, using antibodies against Pol II, P-Ser2 and P-
Ser5 (graphs on the left specified as -DRB). qChIP experiments were performed on the same regions after the treatment with 5,6-
DichloroBenzimidazole Riboside (DBR), an RNA Polymerase inhibitor that prevents Pol II switch from the stalled to the processive conformation 
(graphs on the right specified as +DRB).  
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Figure 12 . DMD intron 34 and exon 45 regions seem exert an enhancer-like activity on luciferase reporter gene expression driven by the Dp427m 
promoter. A) Cartoons describe Luc reporter construct carrying only Dp427m promoter, used as negative control (Dp427m Prom) and the constructs 
containing the DMD intron 34 region (Int 34) cloned downstream of Dp427m promoter. B) Cartoons describe Luc reporter construct carrying only 
Dp427m promoter, used as negative control (Dp427m Prom) and the constructs containing the DMD exon 45 region (Ex 45) cloned of Dp427m 
promoter. For both regions: the orientation with respect to transcriptional direction are indicated as direct (Dir) or inverse (Inv). The full-length 
identified region or its sequential deletions (specified as delta Δ) were tested by transient transfection after 24 hours. Transfections were performed in 
HeLa cell line (drak grey bars) and in Rhabdomyosarcoma SJCRH30 cell line (light grey bars). The negative control activity was arbitrarily set to 1. 
Results are the average of three independent transfection experiments in which each point was analysed in triplicate.  
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Compartmentalization Dynamics of DMD Coding and Non-Coding Transcripts 
after Exon Skipping Treatments  
 
Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin 
gene. With a few exceptions, all DMD mutations (substitutions, deletions and duplications) lead to 
frameshifts, resulting in the formation of premature termination codons that impair dystrophin 
translation. Dystrophin is a cytoskeletal protein located at the inner surface of the plasma 
membrane; in muscle the N-terminus binds F-actin while its cysteine-rich domain, located near the 
C-terminus, interacts with a large oligomeric complex of sarcolemmal proteins and glycoproteins, 
the dystrophin-glycoprotein complex (DGC). This provides a link between the intracellular 
contractile apparatus and the extracellular matrix environment. Immunohistochemical studies have 
shown that in differentiating human skeletal muscle cultures, the sarcolemmal localisation of 
dystophin occurs after myoblasts fuse into myotubes (Chevron et al., 1994; Miranda et al., 1988; 
Torelli et al., 1999). The exon skipping is a promising therapeutic approach for the DMD. It based 
on the skipping of specific mutated exons. This can be obtained by use of  chemically modified 
antisense oligonucleotides (AONs) that, pairing with specific splice junctions or exonic splicing 
enhancers, prevent exon recognition by the splicing machinery. This allows to restore the frame of 
muscular dystrophin transcript, thus resulting in an internally partially truncated but still functional 
dystrophin. Despite the promising potential regarding the exon skipping therapeutic strategy, the 
skipped dystrophin amount is  generally lower than the hoped result. 
Both the export of Dp427m transcript from nucleus into the cytoplasm  and its availability to be 
translated in this compartment belong to an important  aspect regarding the transcriptional dynamics 
of DMD locus. The packaging of mRNA in mature ribonucleoprotein (RNP) complexes and the 
overcoming the nuclear membrane are processes tightly linked to RNA transcription, mRNA 
splicing, correct 3' end formation and mRNA surveillance mechanisms. To understand how these 
phenomena determine the proper amount of dystrophin in a muscle cell, it is important to evaluate 
the general cellular distribution of Dp427m  mRNA.  
To verify the main cellular localization of muscle dystrophin transcript, a compartmentalization 
study was performed in differentiated muscular cells (immortalized human myotubes) by qPCR 
expression analysis. To evaluate the transcriptional distribution, at the steady state, of either 
transcripts starting from regions near the Dp427m promoter or a transcript yielded in a distant point 
from this region, within the DMD locus, the other two full length distrophin isoforms (Dp427c and 
Dp427p) and the Dp71 mRNAs were checked, as well.  
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More importantly, to verify whether the exon skipping therapy could perturb such equilibrium, the 
same in-vitro assay was also carried out after AONs treatment. Essentially, the ultimate aim of this 
compartmentalization analysis was to observe whether exists a link between the export of muscular 
transcript and the low efficiency of exon skipping therapeutic approach in term of final protein 
amount. Since the new identified lncRNAs, ncINT44s, ncINT44s2 and ncINT55s, are involved, as 
in vitro as in vivo, in the transcriptional regulation of muscle dystrophin isoform, they were also 
included in the investigation to study whether  they could be correlated, in some way, to an induced 
re-framing process as well as to the mRNA export.  
Immortalized human myoblasts deriving either from a wild-type individual or from a DMD patient 
(carrying a deletion spanning the exons 48-50) were induced to differentiate into myotubes for 7 
days and then, both fractionated to obtain nuclear and cytoplasmic RNA extracts, before and after 
AON51 treatment (27 hours). In the wild-type myotubes, the AON51 treatment should simulate the 
mRNAs distribution of dystrophic myotubes, since here the skipping of exon 51 generates a non-in-
frame Dp427m transcript. As further control, the wilt-type sample was treated with a second out-
framing AON (AON44), based on the analogous rationale. As a complementary experiment, the 
wilt-type myotubes were also treated with an in-framing AON (AON16). In this case the skipping 
of exon 16 yields a functional dystrophin mRNAs. These latter two treatments were not performed 
in DMD cells because of their extremely reduced potential to differentiate. 
Two types of expression analysis were performed. The first one showed, for each transcript, the fold 
differences intra-compartments (2-ΔΔCt expressed  through percentage values) between the AON-
treated myotubes and the only-PEI treated ones (the transfection agent that we used as control 
condition). In other words, we evaluated the AON/PEI ratio within each nuclear or each 
cytoplasmic RNA fraction. The second one describes the fold differences of each transcript between 
the two compartments (2-ΔΔCt expressed as values of  nuclear enrichment) or in other words the ratio 
between nucleus versus cytoplasm. The latter kind of analysis was also carried out for the lncRNAs, 
although they are essentially localized into the nucleus.   
At first, by running 1ug of total, cytoplasmic and nuclear RNAs on a denaturing agarose gel, we 
evaluated the quality of fractionation technique. The ribosomal RNA (rRNA) is the most abundant 
type of RNA in a eukaryotic cell (it is roughly the 95% of total RNA amount) and it is the only 
RNA specie visible by an elettrophoretic run. The rRNA molecules are differentially distributed 
between the nucleus and the cytoplasm, based on the their status of processing. Specifically, rRNA 
28S and 18S are preferentially present in the cytoplasm, while their unprocessed rRNA precursors, 
at higher molecular weight,  are still retained in the nucleus. Comparing the cytoplasmic and 
nuclear pattern of bands to the total RNA extracted, we could observe that the RNA fractions 
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resulted in a stronger enrichment of one class of molecules than its counterpart (enrichment of 
higher molecular weight rRNAs in nucleus and enrichment of lower molecular weight rRNAs in 
cytoplasm) (Figures 13D, 13E, 13F). At second, to estimate the cellular partitioning we also 
considered the differences of RNA concentration between the two RNA fractions. The cytoplasmic 
and nuclear RNA samples were eluted in the same volume at the final step of each fractionation and 
their concentration was measured by nanodrop. Then, we calculated the ratio between the two 
concentration values. It is known that the cytoplasmic RNA amount is higher than its nuclear 
counterpart, although the relative proportion Cyto:Nucleus changes depending on the cellular type. 
For our differentiated myotubes, the average ratio value of RNA concentration between cytoplasm 
and nucleus was 5:1, confirming this theory and the good partition seen by the electrophoresis 
analysis. 
Analyzing the fold differences of expression between AON- versus PEI-treated nuclear fractions 
(the first qPCR analysis describe above) of the DMD myotubes, we observed that the level of all 
full-lenght isoform transcripts (Dp427c, Dp427m and Dp427p) increase after AON51 treatment. 
Notably, the rates of increase regarding the muscle and purkinje dystrophin isoforms were roughly 
comparable each other (roughly 50% and 40% respectively), while the nuclear accumulation of 
brain isoform is considerable higher (roughly 150% higher than nuclear amount found in PEI-
treated nuclei). The fold differences of expression between AON and PEI conditions in the DMD 
cytoplasmic fractions showed an opposite behavior, as expected. We observed that the AON 
treatment induce decreased levels of all full-length dystrophin transcripts in the cytoplasm  in a 
consistent manner. These results suggest that there is a nuclear accumulation of the transcripts. The 
Dp71 transcript distribution parallels to the other dystrophin isoforms (Fig. 14, graphs on the left 
panel).  
Regarding the M isoform in wild type myotubes, the observed fold differences between AON-
treated nuclei and control PEI-treated nuclei is not dependent on the final effect of exon skipping 
treatment (in frame or not in frame resulting muscular dystrophin transcript). The Dp427m mRNA 
does not accumulate in the nuclei treated with AON44 and AON16 and its cytoplasmic distribution 
is not affected at all by the treatment, suggesting that the axis transcription-export-translation is not 
altered. The skipping of exon 51 in wilt-type myotubes seems to affect very slightly this equilibrium 
(Fig. 14, graphs on the left panel).  
The Dp427c and Dp71 mRNA are still accumulated in the AON44- and AON16-treated nuclei, but 
there is not a correspondent reduction of the transcripts in the cytoplasm. Actually, their levels 
increase in the cytoplasm and in particular the Dp71 transcript accumulate  in all AON-treated wild-
type cytoplasms, suggesting that the export of this dystrophin isoform is enhanced. Also the 
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purkinje dystrophin isoform seems improperly exported in the cytoplasm, while its nuclear 
transcriptional steady-state is not perturbed (Fig. 14, graphs on the left panel). 
As we said before, by the same qPCR analysis, we also evaluated the nuclear and cytoplasmic ratio 
between AON- and PEI-treated myotubes (wild type as well as dystrophic) relative to the regulatory 
lncRNAs transcribed within the DMD locus (ncINT44s, ncINT44s2 and ncINT55s) . We could 
observe a strong accumulation of all non-coding transcripts in DMD nuclei after exon skipping  
(DMD AON51) (Fig. 15, graphs on the left panel).  Moreover, comparing these values to wilt-type 
nuclear AON/PEI ratio counterparts, we could notice that the first ones are considerably higher. 
Importantly, taking into account the DMD nuclear and cytoplasmic fractions, the lncRNAs cellular 
distribution after AON51 treatment mirror that seen for the other full-lenght dystrophins, supporting 
their role as transcriptional regulators of the DMD locus in the dystrophic context, as well.  
In wilt-type samples, the lncRNAs cytoplasmic enrichments found after AON treatments remain a 
controversial question. It is important to underline that they were found as exiguous transcripts in 
the cytoplasmic fractions (late Ct values in qPCR raw data), so these results could be a false 
cytoplasmic enrichments of lncRNAs, due to nuclear contamination of cytoplasmic RNA extracts. 
On the other hand, however, it is not possible to exclude that, in wilt-type myotubes, the AONs 
might induce an improper export of transcripts, coding as well as non-coding. In parallel, as we 
supposed before, an enhanced export seems occur also for the Dp427c, Dp427p and Dp71 mRNAs, 
in wilt-type samples. Importantly, the muscular dystrophin transcript represents the exception to this 
"rule". 
By second type of qPCR analysis we evaluated the fold difference of each transcript between 
nuclear and cytoplasmic compartment. For each experimental condition (untreated, PEI- or AON-
treated myotubes), we pointed to 1 the level of expression of each gene in the cytoplasm and in the 
figure we represented each nuclear fold enrichments (2-ΔΔCt), respectively. In this way, we could 
answer the our first question: "how Dp427m mRNA is distributed  in a muscle differentiated cell?". 
The transcript levels of muscular dystrophin are remarkably enriched in the nucleus in all checked 
experimental conditions. The fold difference is roughly 40:1 between the two compartments in the 
untreated myotubes (denoted as non treated, NT, in the figures). We observed that the other two full 
length dystrophin mRNAs are also nuclear enriched transcripts (Fig. 14, graphs on the right panel). 
Furthermore, we confirmed again the essentially nuclear localization of lncRNAs ncINT44s, 
ncINT44s2 and ncINT55s in muscular differentiated cells, as well. In all experiments (named WT 
AON44, WT AON16, WT AON51 and DMD AON51 in the figures) and for each  experimental 
condition (denoted as NT, PEI or AON), the lncRNAs are 200 fold enriched, at least, but the ratio 
nucleus:cytoplasm reached values of roughly 500:1, as well (Fig. 15, graphs on the right panel). The 
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Dp71 transcript, instead, is equally distributed between the two compartments in differentiated 
muscular cells, showing an average nuclear enrichiment of 2 fold in the wild-type myotubes.  
Overall, in the WT experiments the exon skipping seems not alter the cellular distribution of full-
length dystrophin mRNAs as well as the compartmentalization at steady-state of  the ubiquitous 
dystrophin isoform transcript. Instead, comparing the ratio nucleus:cytoplasm relative to three 
conditions (NT, PEI, AON) obtained for the experiments performed in wild type cells (WT AON44, 
WT AON16, WT AON51) we can see that the lncRNAs (ncINT44s, ncINT44s2 and ncINT55s) are 
less abundant in the nuclear fractions after AON44 and AON16 treatments. Likely, this might be 
due either to nuclear contamination of the cytoplasmic fractions or the improper export of non-
coding RNAs occurring in a wild-type cells, as we speculated before. The AON51 instead did not 
significantly perturb the equilibrium between the two compartments (Fig. 14 and Fig.15, graphs on 
the right panel). 
Comparing the fold differences between the two compartments (the nuclear enrichment, indicated 
as N/C in y-axes of the graphs) obtained in AON51-treated and control treated (PEI) dystrophic 
myotubes (DMD AON51 experiment), we observed that  all full-length dystrophin mRNAs as well 
as all three lncRNAs are strongly compartmentalized in the nuclei after the AON treatment, 
indicating that the transcription-splicing-export axis could be affected by presence of antisense 
oligonucleotides in a dystrophic cellular context. Notably, the Dp71 transcript compartmentalization 
seems be not particularly affected, suggesting that this accumulation does not occurs for transcript 
starting downstream of exon 51 (the first exon of Dp71 is located within intron 62 of full-length 
dystrophin isoform) (Fig. 14 and Fig.15, graphs on the right panel). 
 
Compartmentalization of Skipped Muscular mRNA 
 
To assess whether the exon skipping treatment occurred, we performed immunofluorescence assay 
on DMD myotubes (Figure 13B).  We can see that some dystrophic myotubes was able to restore 
the synthesis of muscular dystrophin protein after AON51 treatment. To quantify the amount of 
skipped muscular dystrophin mRNAs in each nuclear and cytoplasmic fraction, we checked the 
proportion (expressed as percentage) between skipped and non-skipped Dp427m transcript in RNA 
samples obtained from wild-type and dystrophic myotubes, before and after AONs treatment. 
Specific pairs of primers surrounding the region of interest was designed based on the AON used. 
The cDNA obtained from each RNA sample was amplified by PCR and then quantified by 
bioanalyzer (Agilent High Sensitivity DNA chip). The exon skipping efficiency was also evaluated  
in RNA total samples to estimate the overall efficiency of each type of antisense oligonucleotide 
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used, since it is known that, although every exon targeted in vitro should be removed from the 
dystrophin mRNA, some exons are more efficiently excluded than others (Wilton et al., 2007). In 
the total RNA samples, the efficiency of exon skipping was roughly the 5% (quantity of skipped  
versus non-skipped PCR product) for each type of AON treatment (AON16, AON44, AON51). 
Comparing the amount of skipped mRNA between nuclear fractions, we found that it was 5% in 
dystrophic cells while it represented the 8% for the wild type cells treated with AON44 and 
AON51. The AON16, instead, did not work at the same efficiency (only 1% of skipped Dp427m 
transcript relative to nuclear non-skipped mRNA). Interestingly, we could note that the percentage 
of skipped muscular dystrophin mRNA in the cytoplasmic fraction of DMD myotubes was the 
highest (11%), as compared to that obtained in the wilt-type cytoplasmic counterparts. This result 
displays how, in a dystrophic cell, functional Dp427m transcripts are efficiently recognized among 
a myriad of not-functional muscular distrophin mRNAs and exported into the cytoplasm to be 
translated in protein (Fig. 13C). 
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Figure 13. A) Wild type differentiated myotubes cultured after 7 days with growth medium DMEM+2%HS. B) Immunofluorescence staining of 
DMD myotubes carrying a deletion spanning exons 48-50. Upper left panel shows DMD myotubes untreated (NT); upper right panel  shows DMD 
myotubes treated with PEI trasfecting agent only; lower panels represent two fields of  DMD myotubes treated with AON51 that express dystrophin 
protein (marked in red). C) Table shows the proportion (expressed as percentage) between skipped and non-skipped Dp427m transcript in RNA 
samples obtained from wild-type and dystrophic myotubes, before and after AONs treatment. Specific pairs of primers surrounding the region of 
interest was designed based on the AON used. The cDNA obtained from each RNA sample (Tot., Cyto., or Nucl.) was amplified by PCR and then 
quantified by bioanalyzer technologies (Agilent High Sensitivity DNA chip). Tot.= total RNA; Cyto= cytoplasmic RNA; Nucl.= nuclear RNA; NT= 
non treated myotubes; PEI= only PEI-treated myotubes; AON= AON-treated myotubes; WT 16, WT 44, WT 51 indicate the experiments performed 
in wild-type myotubes treated or not with AON16, AON44 and AON51, respectively; DMD 51 indicates the experiment performed in dystrophic 
myotubes treated or not with AON51. D) E) F) Quality of extracted RNAs evaluated by running 1 ug of nuclear and cytoplasmic RNAs on a 
denaturing agarose gel. 28S and 18S ribosomal RNA are indicated as molecular weight markers; T=total RNA, C=cytoplasmic RNA, N=nuclear 
RNA. 
 
52 
 
 
53 
 
Figure 14.  Compartmentalization analysis of Dp427m, Dp427c, Dp427p and Dp71 mRNA isoforms. The graphs represent qRT-PCR expression 
analyses (2-ΔΔCt). GAPDH was used as housekeeping gene. Endogenous expression of Dp427b, Dp427m, Dp427p and Dp71 dystrophin mRNA 
isoforms was determined by qRT-PCR with specific TaqMan systems. Nuclear and cytoplasmic RNA fractions obtained from the experiments 
performed in wild-type myotubes treated or not with AON16, AON44 and AON51 are indicated as WT AON16, WT AON44, WT AON51, 
respectively, on the x-axis. The experiment performed in dystrophic myotubes treated or not with AON51 is indicated as DMD AON51 on the x-axis. 
Graphs on the left: the expression analysis shows, for each transcript, the fold differences intra-compartments (2-ΔΔCt expressed  through percentage 
values) between AON condition and PEI condition (the transfection agent used as control condition). On the y-axis are reported AON/PEI ratio values 
(Fold difference AON/PEI) obtained for each nuclear (red bars) or each cytoplasmic (yellow bars) RNA fraction. Each relative PEI condition was 
pointed to 0% and it does not show in the graphs. Graphs on the right: the expression analysis describes the fold differences of each transcript 
between two compartments (2-ΔΔCt expressed as values of  nuclear enrichment). On the y-axis are reported  the ratio values between nucleus versus 
cytoplasm (Fold difference N/C) for each experimental condition (NT=non treated; PEI= only PEI treated; AON= AON treated myotubes). Each 
relative cytoplasmic value was pointed to 1 and it does not show in the graphs. 
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Figure 15.  Compartmentalization analysis of lncRNAs, ncINT44s, ncINT44s2 and ncINT55s, transcribed within the DMD locus. The graphs 
represent qRT-PCR expression analyses (2-ΔΔCt). GAPDH was used as housekeeping gene. Endogenous expression of ncINT44s, ncINT44s2 and 
ncINT55s lncRNAs was determined by qRT-PCR with specific TaqMan systems. Nuclear and cytoplasmic RNA fractions obtained from the 
experiments performed in wild-type myotubes, treated or not with AON16, AON44 and AON51, are indicated as WT AON16, WT AON44, WT 
AON51, respectively, on the x-axis. The experiment performed in dystrophic myotubes, treated or not with AON51, is indicated as DMD AON51 on 
the x-axis. Graphs on the left: the expression analysis shows, for each transcript, the fold differences intra-compartments (2-ΔΔCt expressed  through 
percentage values) between AON condition and PEI condition (the transfection agent used as control condition). On the y-axis are reported AON/PEI 
ratio values (Fold difference AON/PEI) obtained for each nuclear (red bars) or each cytoplasmic (yellow bars) RNA fraction. Each relative PEI 
condition was pointed to 0% and it does not show in the graphs. Graphs on the right: the expression analysis describes the fold differences of each 
transcript between two compartments (2-ΔΔCt expressed as values of  nuclear enrichment). On the y-axis are reported  the ratio values between 
nucleus versus cytoplasm (Fold difference N/C) for each experimental condition (NT=non treated; PEI= only PEI treated; AON= AON treated 
myotubes). Each relative cytoplasmic value was pointed to 1 and it does not show in the graphs. 
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Discussion 
 
The DMD Locus Harbours Multiple Long Non-Coding RNAs 
 
The dystrophin gene is an extraordinary source of information for unraveling molecular 
mechanisms underlining transcription regulation in humans, as demonstrated by the extreme fine-
tuning of dystrophin transcription, its correlation with specific phenotypes and basic mechanisms, 
and the recent molecular therapy approach based on splicing modulation (Wood et al., 2010). 
Taking all this into account, exploration of the occurrence of regulatory RNAs within this gene 
represents an appealing and obvious target, and their full characterization will surely have great 
impact on our understanding of the genetic programming of the DMD locus. In this context, the 
development of our gene-specific Gene Expression microarray has led for the first time to the 
definition of the contribution of the DMD gene to non-coding RNA production. In fact, we could 
identify 14 non-coding poly A+ transcripts in human adult skeletal muscle, brain, heart and skin 
tissues transcribed mostly within introns and sense-oriented like dystrophin transcripts.  
Tiling arrays of the entire human genome have expanded upon these analyses, detecting messages 
in the liver that map 1,529 and 1,566 novel intronic transcriptionally-active regions, arising, 
respectively, from the antisense or sense strands of the corresponding genes (Nakaya et al., 2007).  
Although several transcribed regions have previously been identified in whole chromosomes, 
including the X chromosome, in a similar fashion, the DMD gene has never before been examined 
in such a detail in human skeletal muscle, brain or heart tissues. By doing so, our approach, has 
allowed the discovery of completely new transcripts for this genomic region that were not identified 
by previous array experiments, thereby demonstrating the sensitivity of our method. Further 
investigations demonstrated that the identified transcripts are mostly tissue-specific, highly 
expressed during myogenesis, and compartmentalised into the nucleus (Bovolenta et al., 2012a). 
 
Architecture, Compartmentalization and Conservation of Long Non-coding RNAs 
in the DMD Gene 
 
ncRNAs are currently categorized on the basis of their structure, and the transcripts we identified 
show several structural features common to many previously characterized lncRNAs. In general, as 
reported for other non-coding transcripts (Pang et al., 2006), our transcripts are poorly conserved. 
Sequence conservation could be relevant for lncRNAs likely to function in trans, where secondary 
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structure is a requirement for the recognition of RNA binding protein targets, and in order to exert 
the specific cellular functions. In fact, lncRNA expression seems to be subject to diverse levels of 
evolutionary constraint in mammals. In general, small ncRNAs such as miRNAs are highly 
conserved, while longer transcripts are less prone to conservation than typical exons. Xist, 
responsible for guiding X chromosome inactivation, and Air, involved in mouse-imprinted gene 
silencing at the Igf2r locus, are examples of poorly conserved lncRNAs. Basing on these 
observations, as well as on our functional data (see below), our DMD lncRNAs seem to belong to 
this latter class of ncRNAs, therefore their regulatory role is expected to be in cis. The length of our 
characterised transcripts ranged from about 1800 to 2800 nt, which is well above the typical length 
reported for exons of protein-coding genes (mean 141 nt). As for several other lncRNAs (Cheng et 
al., 2005; Ginger et al., 2006; Wagner et al., 2007), two of our characterized lncRNAs also exist in 
different isoforms, which are differentially expressed in the tissues studied, presumably reflecting 
tissue-specific functions. Moreover, with the exception of ncINT55as, most identified ncRNAs are 
unspliced, similar to Kcnq1ot1 (Redrup et al., 2009) and MEN epsilon/beta isoforms (Sasaki et al., 
2009). Unbiased analyses have already indicated that a significant proportion of un-annotated 
ncRNAs are exclusively detected in nuclear or cytoplasmic cellular extracts (Cheng et al., 2005; Wu 
et al., 2008). Intronic ncRNA expression seems to be predominantly nuclear, although some subsets 
have primarily been detected in the cytoplasm, and only a few seem to be equally expressed in both 
compartments (Kapranov et al., 2007). Our results are consistent with these observations, since all 
analysed transcripts were found to be mainly, if not exclusively, located in the nuclear compartment 
(Bovolenta et al., 2012a). 
 
DMD lncRNAs Function 
 
lncRNAs are known to be involved in three main functional areas: i) chromatin modification and 
epigenetic regulation; ii) subcellular and structural organisation of transcripts; and iii) regulation of 
expression of neighbouring genes either in cis or in trans (a phenomenon known as transvection) 
(Mercer et al., 2009). Our transcripts were observed to have preferential distribution in proximity to 
the unique first exons of several DMD gene isoforms, as reported for other ncRNAs (Kapranov et 
al., 2007; Nakaya et al., 2007). Interestingly, considering the full repertoire of human lncRNAs, a 
higher proportion of transcripts are mapped to the first introns of protein-coding genes, a region 
relatively close to the promoters. This intense transcription activity of ncRNAs around promoter 
regions appears to relax the chromatin structure, making it more accessible to the transcription 
machinery (Bevilacqua et al., 2003). Nevertheless, a contrasting phenomenon also appears to hold 
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some truth. For instance, a partially intronic ncRNA produced from the genome locus that encodes 
dihydrofolate reductase (DHFR) directly interacts with the DHFR major promoter to reduce the 
expression of the protein-coding RNA (Martianov et al., 2007). Along with the latter line of 
evidence stand our data. Indeed we have shown that forced expression of specific lncRNAs in 
human cells can down-regulate expression of muscle and brain dystrophin isoforms. Apparently this 
negative modulation is achieved through some kind of interaction between the lncRNA and the 
dystrophin promoter region. Although additional work is clearly required to characterize this 
mechanism and to identify the cellular components involved in this phenomenon, nonetheless our 
analyses have revealed that some DMD lncRNAs can specifically target the dystrophin promoter 
and somehow dictate the dystrophin transcription rate. This is also corroborated by the analyses 
performed on muscle samples of DMD female carriers and from indirect observations that, for 
instance, a lncRNA like ncINT1Ms2, whose 3' end overlaps the promoter region of the Dp427p 
full-length dystrophin isoform, is expressed in the heart and in the skeletal muscle where Dp427p is 
not expressed, whereas it is undetectable in the brain where Dp427p is produced. Despite their 
relevance for the biology of the dystrophin gene, our data become particularly significant for a more 
comprehensive understanding of dystrophinopathies and eventually for the better design of the 
therapeutic approaches. For instance a similar scenario to that unraveled by this study has been 
recently highlighted in FSHD, in which ncRNAs were demonstrated to act as repressors of the 
binding copy number variations within the FSHD D4Z4 repeats with implications for the 
transcriptional control of putatively in cis pathogenic genes such as FRG1(Cabianca et al., 2012). 
Moreover, in another study it has been discovered that a particular lncRNA interacting with two 
miRNAs (one of which was enriched in the serum of DMD patients and could be correlated with 
the clinical assessment of the pathology (Cacchiarelli et al., 2011b) can regulate muscle 
differentiation (Cesana et al., 2011), with a plausible impact on the pathogenesis of DMD 
(Bovolenta et al., 2012a). 
 
ChIP-on-chip Analyses of DMD Locus Unravel Novel Unexplored DMD Regions 
 
The strictly association between RNA pol II and almost all molecular processes linked to 
transcription is supported by an inexorable flow of experimental data. Particularly, the dynamic 
phosphorylation of serine residues on the carboxy-terminal domain (CTD) heptad repeats of RNA 
pol II  functions as "landing pad" for the recruitment (either directly or indirectly) of protein factors 
and enzymes that coordinate the entire cycle of transcription: from initiation of transcription to 
elongation, capping, splicing, 3'-end cleavage, polyadenilation, mRNA release and finally its export 
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into the cytoplasm. Moreover, all players that contribute to yield a mature and functional mRNA, as 
well as  the chromatin-modifying enzymes promoting the transcription, are intricately intertwined 
and they influence each others. Thus, a combinatorial study of more determinants becomes a 
precious tool to shed light on the transcriptional dynamics of a gene, especially when the locus of 
interest is so complex  as that encodes dystrophin. Following the extraordinary journey of RNA 
polymerase II along the DMD locus and analyzing the chromatin context within which it works 
allowed us to discover and focus on novel interesting regions, never been considered before.  
 
DMD Intron 52 and Exon 62 Regions  
 
Several efforts were been made to understand the genomic organization of human DMD locus and  
to accurately define the exon-intron boundaries (Coffey et al., 1992; Klamut et al., 1990; Koenig et 
al., 1987; Monaco et al., 1992; Nobile et al., 1995; Roberts et al., 1992). The DMD gene consists of 
79 exons and at least 7 promoters that drives as many different dystrophin isoforms. Their 
transcription is finely regulated in a tissue- and developmental-specific manner. Actually, further 
level of complexity arise from the  fact that the dystrophin gene produces many other isoforms 
generated through alternative splicing events, either excluding some exons from the primary 
transcript (exon skipping) or subverting the reciprocal order of exons (exon scrambling) (Sadoulet-
Puccio and Kunkel, 1996; Surono et al., 1999). These events generate a further level of protein 
diversity and account for the complex expression regulation to which  the dystrophin gene 
undergoes. For this reasons, it is not surprisingly that a so intricate gene could contain additional 
TSS, either of coding or non-coding transcripts. By ChIP-on-chip analyses we identified two 
regions never been associated before with transcriptional activity within the DMD locus. They are 
located around intron 52 and exon 62 regions and displaying  the same pattern of enrichments found 
in the well known TSS of muscular, brain and ubiquitous dystrophin isoforms: the typical 
distribution of RNA polymerase II and its major CTD modifications associated with a promoter 
region (Pol II, P-Ser2, P-Ser5) and strong presence of two markers characterizing an actively 
transcribed chromatin (Ac-H3 and 2Me-H3K4). However, the treatment with the reversible 
inhibitor of new transcription, DRB, allowed to discriminate between the two regions, suggesting 
that the exon 62 can be still considered a putative TSS, while the intron 52 region could be an 
important pausing site where the pol II sit-in to coordinate the multiplicity of events occurring in the 
neighborhood of this portion of the dystrophin gene. 
The strong enrichment for the 3Me-H3K36 mark downstream of exon 62 region and downstream  
of  Dp71 TSS still remain a controversial matter. H3K36me3 modification is found to peak within 
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the body of active genes. Several studies in yeast demonstrated that the levels of H3K36me3 rise 
and fall intermittently within transcribed regions. Notably, exonic regions are more enriched for 
H3K36me3, as compared to intronic segments within the same gene. Moreover, alternatively 
spliced exons showed reduced H3K36me3 levels when compared to exons that are constitutively 
expressed, suggesting that H3K36me3 levels demark which exons are incorporated or removed by 
the splicing machinery. The H3K36me3 pattern of exon marking is evolutionary conserved also in 
mice and human (Kolasinska-Zwierz et al., 2009). Since the rate of transcript elongation seems to 
have an important role in determining specific exon inclusion, it is attractive to speculate that the 
H3K36me3 recognition by chromatin remodeling complexes might influence the rate of RNA pol II 
passage, thus modulating the splicing process (de la Mata et al., 2003; Howe et al., 2003). Based on 
these lines of evidence, the  intragenic 3Me-H3K36 signature around the  DMD exon 62 region and 
Dp71 TSS, might be necessary to allow RNA polymerase II to coordinate the splicing events 
together a new event of transcriptional start. Two important processes are occurring within the same 
temporal window: the recognition of exon/intron splicing junctions during the transcription of the 
full-length brain and muscular dystrophin isoforms (where likely the Pol II pauses) and the 
recognition of a promoter region. However, all these hypothesis remain to be confirmed. 
Additionally, another theory could be hazarded to explain the mean of 3Me-H3K36 mark found in 
these two regions, based on experimental evidence correlating the histone acetylation/deacetylation 
cycle to this type of histone modification. The H3K36me3 is a general hallmark of transcribed 
DNA. It increases toward the 3′ end of genes and then falls sharply in 3′ flanking regions (Barski et 
al., 2007). Similar to histone modifications at promoters, intragenic histones can be acetylated, 
methylated or ubiquitylated with distinct outcomes on gene expression. Histone acetyltransferase 
(HAT) and histone deacetylase (HDAC) complexes are enriched throughout the coding regions of 
actively transcribed genes, suggesting significant co-transcriptional histone remodelling  (Selth et 
al., 2010). Intriguingly, Pol II colocalizes with HATs and HDACs in transcribed sequences during 
elongation cycle. In yeast the Eaf3 subunit of the Rpd3s HDAC complex is assembled at transcribed 
genes through Pol II coupled to H3K36 methylation  (Carrozza et al., 2005; Krogan et al., 2003; Li 
et al., 2007; Li et al., 2003; Xiao et al., 2003). Deletion of Rpd3 resulted in spurious transcription 
from cryptic promoters, suggesting HDACs are required to reestablish repressive chromatin in Pol 
II’s wake (Carrozza et al., 2005). H3K36 di- and tri-methylation recruits the Rpd3s HDAC 
complex, and thereby plays a critical role in repressing cryptic transcription (Carrozza et al., 2005; 
Shukla and Oberdoerffer, 2012). It sounds reasonable speculate that, downstream of an internal 
TSS, H3K36me3 might act as signal to recruit specific HDACs, thus avoiding spurious 
transcription. Also this hypothesis remains to be determined. 
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DMD Intron 34 and Exon 45 Regions  
 
The promoter region is the main responsible DNA sequence that drive the gene  expression, but not 
less important is the contribution of additional cis-regulatory DNA sequences, such as enhancers  or 
silencers. These regulatory elements act independently of their orientation and can significantly 
influence the transcription in a tissue- or developmental-specific manner, although they are located 
at a variable distance from the transcription start site (TSS) of the gene they regulate. Thanks to the 
recent technological advances to map histone modifications and chromatin-associated factors, 
several studies have begun to characterize chromatin signatures of active enhancers, providing a 
more detailed picture of the basic enhancer organizations and functions (Bulger and Groudine, 
2011; Ong and Corces, 2011).  
In our pioneering study, the combination of chromatin immunoprecipitation with microarrays 
(ChIP-on-chip) has proved to be a powerful technique to explore the DMD locus and allows us to 
precisely identify new regions characterized by histone modifications associated with a enhancer 
element. By this experimental strategy it has been possible to restrict the research field and focus 
the attention on specific DMD potential region of interest. The  trimethylation of lysin 4 on histone 
H3 (H3K4me3) is a strong marker found  at promoters and enhancers, and this latter is bound by the 
transcription factor p300, a general transcriptional co-activator (Heintzman et al., 2009; Heintzman 
et al., 2007). The laboratory of Keji Zhao has actually shown that putative enhancer regions are 
enriched in several histone marks, including the three levels of H3K4 methylation, H3K27 
acetylation (H3K27ac) and the histone variant H2A. Z. (Barski et al., 2007; Wang et al., 2008). In 
particular, an active enhancers were found to be generally associated with the presence of both 
H3K4me2 and H3K4me3 and, gain or loss of H3K4me2/3 at distal genomic regions correlated with, 
respectively, the induction or the repression of associated genes during T-cell development 
(Pekowska et al., 2011).  
Notably, the nucleosomes represent the major physical barrier for the access of TFs to their target 
sites in vivo. The positioning of nucleosomes at enhancer elements and the different patterns of 
histone modification might mirror a cell lineage- and developmental-specific regulation of gene 
expression (He et al., 2010; Hu et al., 2011; Schones et al., 2008). 
Based on these several line of evidences, we found that DMD intron 34 and exon 45 regions were 
marked by pan-acetylation and 2Me-K4 of histone H3 in SJCRH30 cell line, while such 
modifications were completely absent in HeLa cells. These findings strongly support the idea that 
these regions might play a role in the transcriptional regulation of Dp427m and Dp427b mRNAs as 
gene-distal cis-regulatory elements. 
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By Dual Luciferase Reporter assays, for each region, the potential enhancer-like regulatory activity  
on brain and muscular promoter was tested in both orientation with respect to direction of 
transcription. Interestingly, the results showed no significant variation in Dp427b promoter activity 
for both regions, while intron 34 as well as exon 45 regions seem positively modulate Dp427m 
promoter (Fig. 12) in both tested cell lines, especially in the rhabdomyosarcoma cells. However, the 
obtained results highlight some questions that have to be solved. The intron 34 region seems exert a 
positive effect in both orientations, although it contributes in a modest manner to the M promoter 
activity. It is possible that the alone co-presence of Dp427m promoter and the putative enhancer 
region is not sufficient to simulate the physiological genomic interaction between the two DNA 
elements. Notably, the cloned cis-regulatory element is missing of those histone marks that might 
be important to recruit specific transcription factors. On the other hand, the exon 45 stimulates the 
muscular promoter in a preferential orientation, thus deviating from the classical definition of 
"enhancer" functionally independent of position and orientation, but the same reasons discussed 
above might be the keystone explaining such behavior. 
 
Nuclear Compartmentalization of Muscular Dystrophin mRNA 
 
In an early study it was observed that mRNAs were accumulated in the nuclear compartment and 
the mature transcripts were the predominantly species, compared to their primary or partially 
spliced counterparts, providing an unexpected view of the nuclei of mammalian cells. The authors 
suggested that the export from the nucleus rather than splicing appears to be the process limiting the 
expression of a large number of genes. The nuclear retention might be an important determinant of 
the nuclear mRNA metabolism (Gondran et al., 1999). By compartmentalization analysis performed 
on wilt-type and dystrophic myotubes, we could observe that the Dp427m  mRNA and the other 
two full-length dystrophin transcript (Dp427c and Dp427p) are confined preferentially in the 
nuclear compartment. Although in our analysis we did not discriminate between processed and non-
processed transcripts, it is reasonable to speculate that their nuclear accumulation might be a 
mechanisms to control the production of dystrophin protein. On the other hand, it is possible that 
full-length transcripts undergo to a slow and finely regulated mRNA processing intimately 
coordinated with the mRNA export pathway. According to this latter hypothesis, the shorter Dp71 
isoform, in fact, is more equally distributed between nucleus and cytoplasm at the steady state, 
indicating a further mRNA metabolism. 
The mRNA can be either committed for export to the cytoplasm or accumulated in the nucleus, 
where it will be degraded. The components of the mRNA transcriptional machinery "communicate" 
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each other to monitor the nascent transcript, thus determining its release from transcription site and 
its further export  into the cytoplasm, where it will be translated  into protein. Practically every step 
of mRNA biogenesis involves rigorous proofreading mechanisms that  safeguard the quality of the 
messenger transcripts and avoid the erroneous export of non functional mRNAs into the synthesis 
compartment. Several studies in yeast demonstrated that both the factors involved in mRNA export 
and the mRNA processing factors take part to and are essential for the development of the mature 
transcript. Many works carried out in different model organisms revealed that the mRNA export 
pathway is conserved from yeast to humans, although every model organism has its own 
peculiarities (Cullen, 2003; Reed and Cheng, 2005; Reed and Hurt, 2002; Stutz and Izaurralde, 
2003). There are four main processing events that occur during the formation of a mature mRNA: 
5'-capping, splicing, 3'-end cleavage and polyadenylation. Each of these modifications impacts 
export. Importantly, 5'-capping  and  mRNA processing events serve as trigger to recruit protein 
factors that are necessary for export (Carmody and Wente, 2009). 
Reed and coworkers  suggested a close link between splicing and mRNA export in higher 
eukaryotes, demonstrating that ALY/REF and UAP56 play a key role in this coupling (Luo et al., 
2001). Subsequent work from several laboratories reported that ALY/REF, UAP56 and TAP–p15 
can associate with the exon-junction complex (EJC).  The metazoan TAP-p15 complex, also known 
as NXF1–NXT1, and its homologous Mex67–Mtr2 complex in yeast,  functions as general mRNA 
export receptors to transport mRNPs through the Nuclear Pore Complexes (NPCs). (Grüter et al., 
1998; Segref et al., 1997). The ALY/REF adaptor (Yra1 in yeast) associates directly with the 
general mRNA exporter and physically interacts with another conserved export fator, UAP56 (Sub2 
in yeast). UAP56 is a RNA helicases that can associate with several complexes involved in 
messenger rinonucleoprotein (mRNP) biogenesis. Finally, the exon-junction complex (EJC) is a 
complex of proteins that is deposited onto mRNA during pre-mRNA splicing (~20–24 nucleotides 
upstream of exon–exon junctions). The EJC remains bound to the mRNA during nuclear export and 
influences surveillance, translation and localization of mature mRNAs in the cytoplasm (Köhler and 
Hurt, 2007; Le Hir et al., 2001). The SR (Ser/Arg-rich) proteins have essential roles in splicing but 
also function as adaptors and regulators of multiple steps of mRNA metabolism including mRNA 
export, stability and translation (Huang and Steitz, 2005). SR proteins are abundant, evolutionarily 
conserved phosphoproteins. After splicing, several SR proteins remain bound to the spliced 
transcript and follow it through the cytoplasm. Here, they dissociate from the transcript and are re-
imported. The phosphorylation status of SR proteins allows them to interact with splicing 
machinery or the general mRNA export receptor TAP–p15 (Huang et al., 2003).  
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The X-linked dystrophin gene (DMD) is the largest gene in the human genome. Its 79 exons cover 
2.5 million base pairs (bp). This large size makes the gene prone to rearrangement and 
recombination events that cause mutations. The main common type of mutations is deletion of one 
or more exons. It occurs in the 60%-70% of the cases. However, duplications, translocations and 
point mutations have also been found. In general, mutations that disrupt the reading frame of the 
dystrophin transcript lead to prematurely aborted dystrophin synthesis and cause the severe 
Duchenne muscular dystrophy (DMD). DMD is the most frequent lethal heritable childhood 
disease. At present, limited and poorly effective therapies exist to treat DMD affected males and 
these are aimed to mitigate the secondary symptoms rather than correct the primary genetic  cause. 
However, the relative new exon skipping strategy is genetic therapeutic approach that is  providing 
promising chances to restore the protein expression in muscle. The mechanism of action is based on 
the use of antisense oligonucleotides (AONs) that, by pairing in a sequence specific manner, target 
a splice site or an exonic splicing enhancer to direct exon skipping during pre-mRNA splicing. This 
allows to produce a shorter, but still functional dystrophin protein, such as patients affected by the 
milder Becker muscular dystrophy form (BMD). Despite the encouraging expectations regarding 
the exon skipping therapy, the skipped dystrophin amount is  generally lower than the hoped result. 
For this reason it is need to understand the molecular limit that impede to achieve higher levels of 
dystrophin protein. Dystrophin is an important structural element in muscle cells that anchors 
proteins from the internal cytoskeleton to those in the fiber membrane. Improving the dystrophin 
synthesis up to 30%, at least, allows to confer significant protection from muscle fiber degeneration 
(Neri et al., 2007).  
To address this issue, we performed compartmentalization analysis on a dystrophic human cellular 
model carrying a deletion of the exons 48-50 in the DMD gene. Specifically, we monitored the 
distribution of Dp427m mRNA between the nuclear and cytoplasmic compartments before and  
after exon skipping treatment with AON51. Through this strategy we could evaluate whether a 
therapy affecting the splicing process could perturb also the mRNA export process, since they are 
strictly linked.  To extrapolate a general mechanisms we took in account also the cellular 
distribution of the other two full-length dystrophin mRNAs (coding for brain and purkinje 
dystrophin isoforms) and the Dp71 transcript (coding for ubiquitous dystrophin). Furthermore, since 
the lncRNAs have been demonstrated to play a variety of roles, being involved in control of gene 
expression (through epigenetic, splicing and transcription mechanisms) and disease modulation, we 
evaluated whether the identified regulatory long non coding RNAs (ncINT44s, ncINT44s2 and 
ncINT55s) transcribed within DMD  could be indirectly involved in a splicing-related therapeutic 
approach. 
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We observed that, in dystrophic myotubes,  all full-length dystrophin mRNAs as well as all three 
lncRNAs are strongly compartmentalized in the nuclei after the AON51 treatment, indicating that 
the transcription-splicing-export axis is affected by presence of antisense oligonucleotides. This 
phenomenon does not occur in a wilt-type muscular context. Intriguingly, the overall 
compartmentalization of the Dp71 transcript seems be not particularly affected. It is reasonable to 
hypothesize  that, within the DMD locus, the transcriptional machinery continues to work in a 
undisturbed manner for transcripts that begin downstream of exon 51 region (the Dp71 starts to be 
transcribed from exon 63) and the linked co-transcriptional processes (including mRNA splicing 
and export) follow their regular flow of events.  
Intriguingly, the lncRNAs cellular distribution after AON51 treatment mirrors the distribution of 
full-lenght dystrophin mRNAs. This support their role as transcriptional regulators of the DMD 
locus in the dystrophic context, as well. In particular, this result might mean that they are involved 
in the compartmentalization regulation of full-length dystrophin transcripts, although it remain to be 
formally demonstrated.  
Finally, regarding the exon skipping therapy, the important results obtained by quantifying the 
amount of skipped M transcript in the DMD cytoplasmic fractions (11%) underlines two essential 
questions: first, in a dystrophic cell, functional Dp427m mRNA molecules are efficiently 
recognized among a myriad of not-functional muscular distrophin transcripts and, second, they are 
exported into the cytoplasm to be translated in protein. Based on these lines of evidence it possible 
to speculate that the events that determine a correct splicing and the relative mRNA export are 
slowed down, likely because the AONs treatment represent an additional event of surveillance that 
occurs in the "defective transcriptional process" of a mutated DMD locus. 
In the future, a detailed analysis dissecting the several factors involved in the splicing and mRNA 
export regulation will be necessary to explain the reason of such increased accumulation of the 
muscular dystrophin mRNA in the DMD context after AONs treatment. This could be the missing 
key to ameliorate the rate of dystrophin synthesis. 
 
 
 
 
65 
 
Materials and Methods 
 
Gene Expression Microarray Design 
We tiled the entire DMD gene, in both sense and antisense directions, using the web-based Agilent 
eArray database, Version 4.5 (Agilent Technologies), with 60-mer oligos every 66 bp of repeat-
masked genome sequence. We defined probe sets for both orientations, encompassing the DMD 
exons, promoters, introns, predicted miRNA (identified by PromiRII in PromiRII website. 
Available: http://cbit.snu.ac.kr/˜ProMiR2/. Accessed 2007 Feb.) and conserved non-coding 
sequences (CNSs) identified within dystrophin introns using the VISTA programme (VISTA 
website. Available: http://genome.lbl.gov/vista/index.shtml). Two specific sets of probes were 
designed to cover, in both directions, the cDNA sequences of a group of control genes (Table S1) 
identified in the Gene Expression Omnibus (GEO) database (GEO website. Available: 
http://www.ncbi.nlm.nih.gov/geo/) and expressed equally in both normal and dystrophic muscles. 
Each probe set was opportunely distributed and replicated several times in order to obtain two 
4×44k microarrays, referred to as DMD GEx Sense (GEO Platform number: GPL13120) and DMD 
GEx Antisense (GEO Platform number: GPL13121), respectively, able to detect transcripts in the 
same and opposite directions as that of DMD gene transcription (Table S2). All the data obtained 
from these platforms are MIAME compliant and can be accessed from the GEO database by 
searching GSE27068 in the GEO accession box. 
 
Sample Processing 
Three commercial poly A+ RNAs from normal human brain, heart and skeletal muscle tissues were 
utilised (Ambion). Skin poly A+ RNA was isolated from total Skin RNA (Stratagene) using the 
Qiagen Oligotex kit. All RNA samples were checked for purity using a ND-1000 spectrophotometer 
(NanoDrop Technologies), and for integrity by electrophoresis on a 2100 BioAnalyzer (Agilent 
Technologies). Sample labelling and hybridisation were performed according to the protocols 
provided by Agilent (One-Color Microarray-Based Gene Expression Analysis version 5.0.1). The 
array was analysed using the Agilent scanner and Feature Extraction software (v9.1). Reliability of 
results was verified via Agilent Quality Controls (Spike-in), consisting of a mixture of 10 in vitro-
synthesized, polyadenylated transcripts derived from the Adenovirus E1A gene, premixed at 
concentrations spanning six logs and differing by one-log or half-log increments. 
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Data Analysis 
We considered aggregate transcription consisting of at least three consecutive probes, whose 
genomic coordinates lay within a 250-nt window, exhibiting fluorescence intensities in the top 90th 
intensity percentile, as described by Bertone et al., 2004 (Bertone et al., 2004). In brief, 
fluorescence intensities for each probe designed within the DMD gene sequence were ranked from 
the lowest to the highest. Values higher than the fluorescence intensity corresponding to 90% of all 
ranked probes on the array were considered as positive hybridisation signals. Subsequently, the 
probes were ordered by their genomic coordinates, and transcripts were identified when at least 
three consecutive probes in a set of 250 base pairs were above the 90th percentile value (Figure 1 
A). Identified transcripts were named according to their intron of origin, with the prefix ‘nc’ for 
non-coding and a suffix corresponding to their sense of transcription (‘s’ for sense and ‘as’ for 
antisense; e.g., ncINT44s is a transcript localized in intron 44 and transcribed in the same direction 
as the DMD gene). 
 
Northern Blotting 
Sense transcripts originating from the intronic regions harbouring the DMD gene isoform promoters 
and antisense transcripts were validated by Northern blotting, using a 12-lane human poly A+ RNA 
filter (Clontech). Riboprobes for ncINT1Ms1, ncINT1Ms2, ncINT1Ps, ncINT29s, ncINT44s1, 
ncINT44s2, ncINT55s, ncINT55as and nc3UTRas were generated, labelled and hybridized to the 
RNA filter. Hybridisation and washing were performed according to the manufacturer’s instructions 
(Clontech), in the presence of herring sperm DNA (10 ug/ul). 
 
RACE PCR 
Rapid Amplification of cDNA Ends (RACE) was performed by using a SMART RACE cDNA 
Amplification Kit (Clontech), according to adapted manufacturer’s instructions. For both 3′-RACE 
and 5′-RACE, 1 µg of poly A+ RNA (Ambion) from skeletal muscle (transcripts ncINT44s1, 
ncINT44s2 and ncINT55s) or heart tissue (transcripts ncINT1Ms2, ncINT55as and nc3UTRas) 
were reverse-transcribed using PrimeScript reverse transcriptase (TaKaRa). For 3′ RACE, cDNAs 
obtained from oligo(dT) extension were amplified in three subsequent PCRs in order to increase the 
degree of reaction specificity. The first amplification was followed by 2 rounds of nested PCRs, 
performed using Nested Universal Primer (NUP) and a gene-specific primer (GSP2 in the first 
round and GSP3 for the second). All PCR amplifications were performed using LA Taq (TaKaRa). 
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For 5′-RACE, first-strand cDNA synthesis was primed using a gene-specific antisense 
oligonucleotide (GSP-RT), and cDNA was tailed with SMARTII oligonucleotide. 5′-RACE was 
performed using the same PCR conditions as for 3′RACE. 
For three transcripts (ncINT44s1, ncINT55s and ncINT1Ms2), a transcript-walking strategy was 
adopted, using the sequence that hybridised on the array as an anchor. For both 3′-RACE and 5′-
RACE, PCR products were purified and sequenced both directly and after cloning into pCRII 
vectors using a TA cloning kit (Invitrogen). All primer sequences used for RACE PCR are listed in 
Table S3. 
 
Bioinformatics Prediction 
The ncRNAs characterized by RACE PCR were tested for secondary structure with mFOLD 3.2 
(mFOLD 3.2 website. Available: http://mfold.rna.albany.edu/?q=mfold/RNAFolding-Form), 
presence of ORF using NCBI ORF Finder (NCBI ORF FINDER website. Available: 
http://www.ncbi.nlm.nih.gov/projects/gorf/) and the Coding Potential Calculator (Coding Potential 
Calculator website. Available: http://cpc.cbi.pku.edu.cn/) and presence of tRNA by TRNAscan-SE 
1.21 (TRNAscan website. Available: http://lowelab.ucsc.edu/tRNAscan-SE/). To determine 
whether our transcripts overlapped any previously annotated ESTs or mRNA, we employed the 
UCSC Genome Browser to inspect our ncRNAs and identify any spliced and unspliced human 
ESTs and mRNAs. 
 
lncRNAs Expression and Compartmentalization Analysis 
Total RNA was purified from human RD and SJCRH30 rhabdomyosarcoma cell lines, SH-SY5Y 
neuroblastoma cell line and both normal and MyoD-induced fibroblasts (transformed with an Ad5-
derived, EA1-deleted adenoviral vector carrying the MyoD gene as previously described in (Spitali 
et al., 2009) using TRi-REAGENT (Sigma Aldrich) and treating with DNAse I (Ambion). Reverse 
transcription (RT) was performed using random hexanucleotide primers and Superscript III enzyme 
(Invitrogen). Real-time PCR was performed in triplicate in a 96-well plate; each 25 µl reaction 
consisted of 1X Taqman Master Mix (Applied Biosystems), 300 nM forward and reverse primers, 
100 nM Taqman probes and 40 ng of cDNA. 
To characterise the intracellular compartmentalisation of the ncRNAs, nucleic and cytoplasmic 
RNA fractions were separated from 1×107 cells (SJCRH30, RD, SH-SY5Y) by glucose gradient 
centrifugation as previously reported (Carneiro and Schibler, 1984), and purified using TRi-
REAGENT (Sigma Aldrich). RNA was treated with DNAse I (Ambion), and reverse transcribed 
68 
 
using random exanucleotide primers and Superscript III enzyme (Invitrogen). Real-Time PCR was 
performed as previously described. The relative quantity of the target sequence (non-coding RNA) 
is expressed as the relative distribution of each single sequence in the nucleic or cytoplasmic 
fraction. Sequences of Taqman probes and amplifying primers are listed in Table S4. 
Expression of the different dystrophin isoforms was determined by standard qRT-PCR. 250 ng of 
cDNA derived from total RNA was amplified by PCR using Taq DNA polymerase recombinant 
(Invitrogen) according to the manufacturer’s instructions. Primer sequences are listed in Table S5. 
To determine the inclusion of the DMD ncRNAs within the full-length dystrophin transcript, we 
amplified by RT-PCR the exons adjacent to the introns in which we identified our ncRNAs. The 
regions amplified were exons 1–3; 28–30; 31–33; 36–38; 43–45; 50–52; 54–56 and 66–68. Primers 
sequences are available upon request. 
 
lncRNA Expression Vectors and Transient Transfections in Cultured Human Cells 
The expression plasmids pcDNA3.1(+)-ncINT44s, pcDNA3.1(+)-ncINT44s2, pcDNA3.1(+)-
ncINT55s and pcDNA3.1(+)-nc3UTRas were generated by cloning the PCR product of each 
ncRNAs into the pcDNA3.1(+) vector (Invitrogen). The template used for PCR amplification was 
genomic DNA extracted from a healthy human male. Primers listed in Table S6 contain the 
appropriate restriction enzyme at 5′-end to facilitate cloning. 
SJCRH30 Rhabdomyosarcoma and SH-SY-5Y Neuroblastoma cell lines were transiently 
transfected using Lipofectamine2000 according to manufacturer’s instructions (Invitrogen). Cell 
cultures were harvested after 48 hours and RNA extracted. Each transfection was repeated three 
time and each point of RT-PCR was performed in triplicate. Statistical analyses were performed 
using one-way ANOVA with Dunnett’s test. 
 
DMD Gene Micro Fluidic Card (FluiDMD v1.1) Analysis 
We explored all transcripts originating from the DMD locus, including the lncRNAs identified by 
our array as well as the whole exome of the dystrophin gene, using a slightly modified design of our 
FluiDMD card already reported (Bovolenta et al., 2012b). We replaced the replicated junction 
systems with specific systems able to detect the following ncRNAs: ncINT1Ms1, ncINT1Ms2, 
ncINT1Ps, ncINT44s1, ncINT44s2, ncINT55s, ncINT55as and nc3UTRas. The fluidic card 
protocol was performed as described in (Bovolenta et al., 2012b). We used these novel card 
(FluiDMD-ncRNAs) both in muscle biopsies and cells from dystrophinopathic patients. We 
analysed seven DMD females’ muscle biopsies. The females were previously selected and known 
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being either symptomatic or asymptomatic carriers (Table 2). Total RNA was obtained from muscle 
biopsy of the seven females, carriers of mutations in the DMD gene as previously described 
(Brioschi et al., 2012). 
 
Reporter vectors and luciferase assay 
The pGL3-basic, pGL3-Sv40promoter and Renilla-TK vectors were purchased from Promega. 
Promoter of selected Dp427m isoform was obtained using PCR and cloned into the pGL3-basic 
vector. The template used for PCR amplification was  genomic DNA extracted from a healthy 
human male.  pGL3-DMDm and pGL3-Sv40promoter were co-transfected with Renilla-TK vector, 
lncRNA expression vectors or pcDNA3.1(+) empty vector in SH-SY-5Y Neuroblastoma cells and 
C2C12 myoblast cells using Lipofectamine2000 (LifeTechnologies) according to manufacturer 
instructions’. The activity of firefly or Renilla luciferase was measured 24h after transfection with a 
dual luciferase assay kit (Promega) according to the instructions. The assay was repeated three 
times. Statistical analyses were performed using one-way ANOVA with Dunnett's test. 
The DMD intron34 and exon 45 regions were cloned in pGL3-DMDm Promoter and the relative 
deleted constructs were obtained by Whole Around PCR. Each plasmid (the pGL3-DMDm 
Promoter alone, the pGL3-DMDm Promoter_intron34 or relative deleted constructs, the pGL3-
DMDm Promoter_exon45 and relative deleted constructs) were co-transfected with Renilla-TK 
vector in HeLa cells and Rhabdomyosarcoma cell line (SJCRH30) using Lipofectamine2000 
(LifeTechnologies) according to manufacturer instructions’. The activity of firefly or Renilla 
luciferase was measured 24h after transfection with a dual luciferase assay kit (Promega) according 
to the instructions. The assay was repeated three times. All Primers used for cloning are listed in 
Table S7. 
 
Cell culture and treatments 
Human rhabdomyosarcoma SJCHR30 cells were cultured in Dulbecco's modified Eagle's medium 
containing 10% fetal bovine serum and 50 mg/ml gentamycin and grown at 37 ºC and 7% CO2. 
Human HeLa cells were cultured in Dulbecco's modified Eagle's medium containing 10% heat-
inactivated fetal bovine serum and 50 mg/ml gentamycin and grown at 37 ºC and 5% CO2. 5,6-
DICHLOROBENZIMIDAZOLE RIBOSIDE (DBR) were purchased from Sigma-Aldrich and cells 
were treated for 6h at 100uM before performing qChIP 
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qChIP  
ChIP was performed as previously described (Weinmann and Farnham, 2002).The antibodies 
employed in this study were: Anti-RNA polymerase II Abcam (ab76123), Anti-RNA polymerase II 
CTD repeat YSPTSPS (phospho S2) Abcam (ab5095),Anti-RNA olymerase II CTD repeat 
YSPTSPS (phospho S5) Abcam (ab5131), Anti-AcethylHistone H3 Upstate (06-599), Anti-
DimethylHistone H3 (Lys4) Upstate (07030), Anti-TrimethylHistone H3 (Lys 36) Abcam (ab9050).   
Specific pairs of primers used for quantitative ChIP are listed in  Table S8. 
 
ChIP-on-chip 
Immunoprecipitated DNA from ChIP was amplified with GenomePlex® Whole 
GenomeAmplification (WGA) Kit according to manufacturer's instructions. Labelling and 
hybridisation were performed following the protocols provided by Agilent (Agilent Oligonucleotide 
Array-Based CGH for Genomic DNA Analysis protocol v5.0). The array was analysed with the 
Agilent scanner and the Feature Extraction software (v9.1). A graphical overview and analysis of 
the data were obtained using the Agilent Genomic Workbench software (v3.5). 
 
Immortalized human myoblasts 
The wild-type (any genetic defect in dystrophin gene) and DMD (deletion of exons 48-50 in 
dystrophin gene) immortalized human myoblasts were obtained as described in (Mamchaoui et al., 
2011) and kindly provided to Section of Medical Genetics, University of Ferrara. 5x104 cells were 
plated in a six well. Five six wells were used for each experimental condition (untreated, PEI-
treated and AON-treated). 
The cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum 
and 50 mg/ml gentamycin and grown at 37 ºC and 5% CO2. Differentiation was induced at 
confluence by replacing the growth medium with DMEM supplemented with 100 μg/ml transferrin, 
10 μg/ml insulin 50 μg/ml of gentamycin and 2% Horse Serum (Sigma-Aldrich) for 7 days. The 
myotubes were treated with PEI transfection agent alone or with antisense oligonucleotides for 4 
hours at 37 ºC and 5% CO2. The myotubes were washed and cultured for 27 hours after treatment 
under differentiation conditions. Nucleic and cytoplasmic RNA fractions were separated by glucose 
gradient centrifugation as previously reported (Carneiro and Schibler, 1984), and purified using Tri-
REAGENT (Sigma Aldrich). RNA was treated with DNAse I (Ambion), and reverse transcribed 
using oligo dT and random primers and iScript Reverse Transcription Supermix (Bio-Rad). 
Sequences of Taqman probes and amplifying primers are listed in Table S4. 
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Byoanalyzer analyses 
To determine the skipped and non-skipped full-length M dystrophin transcript, we amplified by 
PCR the region surrounding the exon of interest. Specific pairs of primers was designed based on 
the AON used. The cDNA obtained from each RNA sample was amplified by PCR (Platinum®Taq 
DNA Polymerase, Life Technologies) and then quantified by bioanalyzer (Agilent High Sensitivity 
DNA chip). The amplified regions spanning: exons 46-52 to obtain a product of 840bp (non-
skipped) and 610bp (skipped) in wild-type cDNA; exons 46-52 to obtain a product of 540bp (non-
skipped) and 310bp (skipped) in DMD cDNA; exons 43-45 to obtain a product of 320bp (non-
skipped) and 170bp (skipped); exons 12-17 to obtain a product of 700bp (non-skipped) and 520bp 
(skipped); 
 
Table S1 
Accession numbers and names of genes used as controls in the custom-designed DMD-GEx 
microarrays. (doi:10.1371/journal.pone.0045328.s005) 
  
NM_004748.3  Cell cycle progression 1 (CCPG1) 
NM_003047.2 Solute carrier family 9 (sodium/hydrogen exchanger)(SLC9A1) 
NM_004045.3 ATX1 antioxidantprotein 1 homologue (ATOX1) 
NM_002766.1 Pyrophosphate synthetase-associated protein 1 (PRPSAP1) 
NM_001428.2 Enolase 1, (alpha) (ENO1) 
NM_003095.2 Small nuclear ribonucleoprotein polypeptide F (SNRPF) 
NM_001914.2 Cytochrome b5 type A (microsomal) (CYB5A) 
NM_000426.3 Laminin, alpha 2 (merosin, congenital muscular dystrophy) (LAMA2) 
NM_003279.2 Troponin C type 2 (fast) (TNNC2) 
NM_003280.1 Troponin C type 1 (slow) (TNNC1) 
NM_003281.3 Troponin I type 1 (skeletal, slow) (TNNI1) 
NM_001101.2 Actin, beta (ACTB), 
NM_002046.3 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
NM_006275.4 Splicing factor, arginine/serine-rich 6 (SFRS6) 
NM_005626.3 Splicing factor, arginine/serine-rich 4 (SFRS4) 
 
Table S2 
Name, number of probes and reiteration of each probe set within the 4x44k sense and antisense 
DMD gene expression microarrays. (doi:10.1371/journal.pone.0045328.s006) 
Probe set name N° of probes Replicated in 
DMD GEx 
sense 
Replicated in 
DMD GEx 
antisense 
Sense DMD 14928 2 0 
Sense DMD exons 174 8 8 
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Table S3 
Name and nucleotide sequence of the primers used for 5′ and 3′ RACE 
(doi:10.1371/journal.pone.0045328.s007)  
 
Primers used for 3’ RACE 
Primer Nucleotide sequence (5’-3’) 
T2_GSP1  cgccctcgagctaggacatggaac 
T2_GSP2  tcacatttaagagggaaggagaaacgcc 
T2_GSP3 (3’)  cccaccaacacctcctgttctctcc  
44_8GSP1  aaatccatattcctgggggcgatgc 
44_8GSP2  cgaaggtgcagccagactgggagtt 
44_8GSP3 (3’)  tgtgggactgcctcttgctcctgaca  
44_9GSP1  cccagaaggggccttgtctgaagtg 
44_9GSP2  ccagcggattacggtgtgggtgaat 
44_9GSP3 (3’)  tcagggatgctgctgctctctaggc  
55_11GSP1  ggttatgcttcccgtctcttcacagagc 
55_11GSP2  cccacgatctggaacagactggcggata 
55_11GSP3 (3’)  ccgcaataactctgtgaagtgctg  
AS55_GSP1  aggacatgaatggatgataatttgtggg 
AS55_GSP2  gaaaagcatgccataagctgttcttagc 
AS55_GSP3 (3’)  tggagcagtgaaaagtagattttggtgtcg  
AS3UTR_GSP1  cagggatgggctgggaatccatag 
AS3UTR _GSP2  ggcattgctagcagcaggaagctg 
AS3UTR _GSP3 (3’) ctgccccactcagctgacagttctc 
 
Primers used for 5’ RACE 
Primer Nucleotide sequence (5’-3’) 
T2_GSPRT  gatgcggaaatttcatttgg 
T2_TWrev  ttagcatgccctttcaatcag 
T2_TW1  ccagagctaatgaggccaag 
T2_TW2  tgagctccaatctcctcacc 
T2_TW3  tcagttgattctgatgagcacc 
T2_GSP1  caggtgaggagattggagctcagagagg 
T2_GSP2  gcccctagacccgtggttctccaac 
T2_GSP3 (5’)  aacccagtgcccaaactgcacttca 
44_8GSPRT  ccctcttttctaccttctaggc 
44_8TWrev  ggacaaaagggttgcacagt 
Sense DMD CNS 2411 3 0 
Sense DMD MiR 51 9 0 
Sense DMD promoters 34 8 0 
Sense Controls 295 8 5 
Antisense DMD 14914 0 2 
Antisense DMD CNS 2421 0 3 
Antisense DMD exons 169 4 3 
Antisense DMD promoters 53 0 8 
Antisense DMD MiR 51 0 8 
Antisense Controls 311 5 8 
 Total 43803 43785 
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44_8TW1  aggtagtccattttgcatcagg 
44_8TW2  aacaaaacctccccaatgc 
44_8TW3  tcattctgagaaccacatctgc 
44_8GSP1  cagcttgaaatatgtgcattggggagg 
44_8GSP2  ttgagtggggcaatttctggcagg 
44_8GSP3 (5’)  tggcaggtggggaagagagtaaagaag 
44_9GSPRT  cagttccattctccacagg 
44_9GSP1  ttcatccactgatggacgtttaggttg 
44_9GSP2  tagtgggattgctggatcatctggtagc 
44_9GSP3 (5’)  aaagcaagacaggtcaacaaaggccag 
55_11GSPRT  gttcagactatgtccatacacagg 
55_11TWrev  tctgtgaagagacgggaagc 
55_11TW1  gggtcacaaacgtgaaggtc 
55_11TW2  ccttccagattcagcatgtg 
55_11TW3  tatctctaggccgtcggttc 
55_11GSP1  tcctgctttctcttccttgggttgc 
55_11GSP2  cagccatggcctcacataggtgg 
55_11GSP3 (5’)  cccgagtagctgatgtcccttcagc 
AS55_GSPRT  agctacaagctgctagacagg 
AS55_GSP1  caaataagctgttggtggcaggaggtg 
AS55_GSP2  tcagcatttcccaggaagggtgatg 
AS55_GSP3 (5’)  gggtcaagaatgcgaaggtcaaggag 
AS3UTR_GSPRT tctctgcgagtagttccacac 
AS3UTR_GSP1 gcttttggagagtgggctgacatcaagtg 
AS3UTR _GSP2 tgcacacctgagttcacagcttcacc 
AS3UTR _GSP3 (5’) tgacgctggaccttttctttacccaagg 
 
Table S4 
Name and sequence of the TaqmanRealTime systems used for the ncRNAs compartmentalisation 
study and dystrophin transcripts expression levels. (doi:10.1371/journal.pone.0045328.s008) 
 
Primer Name and Sequence 
ncINT1Ms2_F TTTGGATGCAGTACTCTTTGTAGACA 
ncINT1Ms 2_R GGAGGTGTTGGTGGGAAAAA 
ncINT1Ms 2_Probe 6-FAM-AATACGGTACGATTAATG 
ncINT44s_F  GGCTCCCTCATTCAATGAATCTA 
ncINT44s_R  CAGCAAAAGATGTCAGGAGCAA 
ncINT44s_Probe 6-FAM-ACTATGTGGGACTGCCT 
ncINT44s2_F  ACCAGGAGCTCTGCTTGCAT 
ncINT44s2_R  TTGTGCATGATAATGTGCCTCAA 
ncINT44s2_Probe 6-FAM-CTGGGAGTTGCCCATG 
ncINT55s_F  TGATAACTTTCATGCCCATTAACATAG 
ncINT55s_R  AACAGGACACAAATTCAGCACTTC 
ncINT55s_Probe 6-FAM-ACCGCAATAACTCTG  
ncINT55as_F  CATTTAGAGCAAGAGATACAGGCATT 
ncINT55as_R  GGGCACAAAAAAGAATAATTTGCTA 
ncINT55as_Probe 6-FAM-AATGTATTACACTGCTACTAAAG 
Dp427b_F  TTGATTTGTTACAGCAGCCAACTT 
Dp427b_R  CTTCCATGCCAGCTGTTTTTC 
Dp427b_Probe 6-FAM TGGCATGATGGAGTGACA 
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Dp427m_F  GAAGAACTTTTACCAGGTTTTTTTTAT 
Dp427m_R  CTTCTTCCCACCAAAGCATTTT 
Dp427m_Probe 6-FAMTGCCTTGATATACACTTTT 
Dp427p_F  CATAGAATGTGTAAGAGAAAAGTACCAACA 
Dp427p_R  GCTGGCTACACACCTTCATAGGA 
Dp427p_Probe 6-FAM AAATCAGCAAAAAGC 
Dp71_F  TGCAGCCATGAGGGAACAG 
Dp71_R  GGATGGTCCCAGCAAGTTGT 
Dp71_Probe  6-FAM TCAAAGGCCACGAGACT 
 
Human ACTB  4352035E (Life Technologies, Catalog Number) 
Human GAPDH 4333764F (Life Technologies, Catalog Number) 
 
 
Table S5 
Name and sequence of the primers used to amplify the DMD gene isoforms in cDNA samples. 
(doi:10.1371/journal.pone.0045328.s009) 
 
Primer Name and Sequence 
Dp427bFw CGTATCAGATAGTCAGAGTGGTTAC 
Dp427mFw CCTGGCATCAGTTACTGTGTTGAC 
Dp427p2Fw CCTATGAAGGTGTGTAGCCAGCC 
Dp427Rv CCATCTACGATGTCAGTACTTCC 
Dp260Fw AGGAACATTCGACCTGAGAAAG 
Dp260Rv TCCACCTTGTCTGCAATATAAGC 
Dp140Fw ATTGCTGGCTGCTCTGAACTAA 
Dp140Rv CATCTGTTTTTGAGGATTGCTG 
Dp116Fw GGGTTTTCTCAGGATTGCTATG 
Dp116Rv CCGGCTTAATTCATCATCTTTC 
Dp71Fw GAAGCTCACTCCTCCACTCGTA 
Dp71Rv AGCCAGTTCAGACACATATCCAC 
GAPDH Fw CATGGGGAAGGTGAAGGTC 
GAPDH Rv AACAATATCCACTTTACCAGAGTT 
 
Table S6 
Name and sequence of primers used for DMD ncRNAs cloning into pcDNA3.1(+) 
(doi:10.1371/journal.pone.0045328.s010) 
 
Primer Name and Sequence 
ncINT44s(EcoRI)_F  AGAATTCGGGATATGAGATGTTGGAAG 
ncINT44s(EcoRI)_R  AGAATTCGTCTTGACTACAGATGTCTTTT 
ncINT44s2(BamHI)_F AGGATCCGCCACTAATTCTTATTGCCATTTC 
ncINT44s2(BamHI)_R AGGATCCAAAGGGCTGCTACAGCTATTTT 
ncINT55s(EcoRI)_F  AGAATTCCATTTTGCTGCACAATAAACAACC 
ncINT55s(EcoRI)_R  AGAATTCCAAGGCATTAAAATCTGCATGATG 
nc3UTRas(EcoRI)_F  AGAATTCGGTGGTTATAAAGAACACAACACG 
nc3UTRas(EcoRI)_R  AGAATTCGGCGTGATATCCATATGAAATTCAT 
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Table S7 
Primer Name and Sequence used for cloning:  
Dp427m Promoter in pGL3-basic; DMD intron34 or its relative deleted sequence downstream of 
the luciferase sequence driven by Dp427m Promoter in pGL3-basic; DMD exon45 or its relative 
deleted sequence downstream of the luciferase sequence driven by Dp427m Promoter in pGL3-
basic 
DMDm Prom.(KpnI)_ F    gatggtaccGGTGCTTTAGACATTACCCAGGACA 
DMDm Prom.(BglII)_ R  tacagatctGGGGGAAAGTGAGTGATCCCAACA 
DMD ex34/35 (BamHI)_F catggatccTGACAAAGCAGTTCTTGAGAGAAGAG 
DMD ex34/35 (BamHI)_R gacggatccAGTGACTCCAATGGCATGTAACAGA 
DMD ex45 (BamHI)_F gacggatccAACATGGAACATCCTTGTGGGGACA 
DMD ex45cl (BamHI)_R catggatccAGGCTATAATTCTTTAACTTTGGCAAGGG 
Int34 Δ1&Δ2 For  CTTTCTGTTTGCCTGTGGTTTTC 
Int34 Δ1 Rev   ACAGGCGGTAGGATGAACATAC 
Int34 Δ2 Rev   CAGACTGTAGTAGGTGATAGATAC 
Ex45 Δ1&Δ2 For  CCAGTTGTTGATGTTAATGTGTCTTG 
Ex45 Δ1 Rev   GAAGATATTCACCTTTAAGCAATC 
Ex45 Δ2 Rev   TCCTGGAGTTCCTGTAAGATACC 
 
Table S8 
qChIP primers  
 
Int 53 A For  GATGAAACTAATGGACTGTGACC 
Int 53 A Rev  AGCCTGTATTGTGGAAGAAGC 
Int 53 B For  GGTAAAGAACAAGGGCAAAGC 
Int 53 B Rev  ATCAGTGACCACCCAAGAGG 
Int 53 C For  TGGAAAACGACTGAACTTGAAG 
Int 53 C Rev  AGAGATTATGAAAGAGAGGAGAGG 
Ex62  A For  GTATCGTAATCACTCAATATCCTC 
Ex62  A Rev  CACTCAGTATTTGTCACCTAAC 
Ex62  B For  TTCTTAAAAGTCGTTCCCCATTG 
Ex62  B Rev  AGAGCATTTATTGTGACTAACCTG 
Ex62  C For  ATGAAGACAGGATGGATTAACC 
Ex62  C Rev  GGGAGACACATACAAGAAACC 
GAPDH TSS For  AAGACCTTGGGCTGGGACT 
GAPDH TSS Rev  GCTGCGGGCTCAATTTATAG 
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